

**Manipal Hospitals Private Limited**  
Balance Sheet as at

|  | Note | (₹ in crores)   |                 |
|--|------|-----------------|-----------------|
|  |      | March 31, 2025  | March 31, 2024  |
| <b>ASSETS</b>  |      |                 |                 |
| <b>Non-current assets</b>  |      |                 |                 |
| Property, plant and equipment  | 3.1  | 752.97          | 726.41          |
| Capital work-in-progress   | 3.2  | 13.33           | 9.66            |
| Right-of-use assets  | 4.1  | 393.13          | 403.97          |
| Intangible assets  | 4.2  | 27.80           | 38.31           |
| <b>Financial assets</b>  |      |                 |                 |
| Investments  | 5.1  | 730.40          | 726.68          |
| Loans  | 5.2  | 12.41           | 33.46           |
| Other financial assets   | 5.3  | 25.60           | 24.69           |
| Deferred tax assets (net)  | 16   | 16.56           | 14.44           |
| Income tax assets (net)  | 6    | 11.25           | 58.64           |
| Other non-current assets   | 7    | 20.12           | 2.77            |
|  |      | <b>2,003.57</b> | <b>2,039.03</b> |
| <b>Current assets</b>  |      |                 |                 |
| Inventories  | 9    | 31.37           | 27.27           |
| <b>Financial assets</b>  |      |                 |                 |
| Investments  | 10.1 | 399.07          | 61.40           |
| Trade receivables  | 10.2 | 109.47          | 84.31           |
| Cash and cash equivalents  | 10.3 | 65.21           | 60.94           |
| Bank balances other than cash and cash equivalents                                       | 10.4 | -               | 7.90            |
| Loans  | 10.5 | 0.26            | 0.20            |
| Other financial assets   | 10.6 | 12.52           | 3.89            |
| Other current assets   | 11   | 10.55           | 29.75           |
|  |      | <b>628.45</b>   | <b>275.66</b>   |
| Assets held for sale   | 8    | 6.50            | 6.50            |
| <b>Total assets</b>  |      | <b>2,638.52</b> | <b>2,321.19</b> |
| <b>EQUITY AND LIABILITIES</b>  |      |                 |                 |
| <b>Equity</b>  |      |                 |                 |
| Equity share capital   | 12   | 1,025.30        | 1,025.30        |
| Other equity   | 13   | 225.33          | (104.87)        |
| <b>Total equity</b>  |      | <b>1,250.63</b> | <b>920.43</b>   |
| <b>Liabilities</b>   |      |                 |                 |
| <b>Non-current liabilities</b>   |      |                 |                 |
| <b>Financial liabilities</b>   |      |                 |                 |
| Borrowings   | 14.1 | 407.99          | 374.42          |
| Lease liabilities  | 14.2 | 574.16          | 558.02          |
| Provisions   | 15   | -               | 7.71            |
|  |      | <b>982.15</b>   | <b>940.15</b>   |
| <b>Current liabilities</b>   |      |                 |                 |
| <b>Financial liabilities</b>   |      |                 |                 |
| Borrowings   | 17.1 | 61.47           | 54.68           |
| Lease liabilities  | 14.2 | 11.69           | 11.49           |
| Trade payables   | 17.2 |                 |                 |
| - total outstanding dues of micro enterprises and small enterprises                      |      | 6.11            | 5.40            |
| - total outstanding dues of creditors other than micro enterprises and small enterprises |      | 268.89          | 352.26          |
| Other financial liabilities  | 18   | 22.56           | 8.56            |
| Other current liabilities  | 20   | 20.17           | 16.99           |
| Current tax liabilities (net)  | 21   | 1.78            | 0.47            |
| Provisions   | 19   | 13.07           | 10.76           |
|  |      | <b>405.74</b>   | <b>460.61</b>   |
| <b>Total equity and liabilities</b>  |      | <b>2,638.52</b> | <b>2,321.19</b> |
| <b>Material Accounting policies</b>  | 2.2  |                 |                 |

The accompanying notes are an integral part of financial statements

As per our report of even date attached

**For B S R & Co. LLP**

Chartered Accountants

Firm Registration number : 101248W/W - 100022



Siddhartha Sharma

Partner

Membership number: 118756

**For and on behalf of the Board of Directors of**  
**Manipal Hospitals Private Limited**



Sameer Agarwal

Director

DIN: 07554053



Dr. H. Sudarshan Ballal

Director

DIN: 01195055



Khadija G Vahora

Company Secretary

Membership number: A37266

Place : Bengaluru

Date : May 27, 2025

Place : Bengaluru

Date : May 27, 2025

**Manipal Hospitals Private Limited**  
**Statement of Profit and Loss for the year ended**

(₹ in crores)

|  | Note | March 31, 2025  | March 31, 2024  |
|--|------|-----------------|-----------------|
| <b>Income</b>  |      |                 |                 |
| Revenue from operations  | 22   | 2,153.75        | 1,787.81        |
| Other income   | 23   | 19.26           | 17.24           |
| Finance income   | 24   | 6.10            | 12.84           |
| <b>Total income</b>  |      | <b>2,179.11</b> | <b>1,817.89</b> |
| <b>Expenses</b>  |      |                 |                 |
| Purchase of medical consumables and pharmacy items                         |      | 367.23          | 315.71          |
| Changes in inventories of medical consumables and pharmacy items           | 25   | (4.10)          | 0.43            |
| Employee benefits expense  | 26   | 240.97          | 209.71          |
| Finance costs  | 27   | 116.89          | 123.70          |
| Depreciation and amortisation expense                                      | 28   | 125.63          | 105.48          |
| Other expenses   | 29   | 886.95          | 746.63          |
| <b>Total expenses</b>  |      | <b>1,733.57</b> | <b>1,501.66</b> |
| <b>Profit before tax</b>   |      | <b>445.54</b>   | <b>316.23</b>   |
| <b>Tax expense</b>   |      |                 |                 |
| Current tax  | 16   | 116.11          | 92.89           |
| Deferred tax   | 16   | (1.79)          | (10.63)         |
| <b>Total tax expense</b>   |      | <b>114.32</b>   | <b>82.26</b>    |
| <b>Profit for the year</b>   |      | <b>331.22</b>   | <b>233.97</b>   |
| <b>Other comprehensive income (OCI)</b>                                    |      |                 |                 |
| <b>Items that will not be reclassified subsequently to profit or loss:</b> |      |                 |                 |
| Re-measurement loss of defined benefit plans                               |      | (1.35)          | (0.83)          |
| Income tax effect on above   |      | 0.33            | 0.21            |
| <b>OCI for the year (net of tax)</b>                                       |      | <b>(1.02)</b>   | <b>(0.62)</b>   |
| <b>Total comprehensive income for the year</b>                             |      | <b>330.20</b>   | <b>233.35</b>   |
| <b>Earnings per equity share</b>   |      |                 |                 |
| [nominal value of share ₹ 10 (March 31, 2024: ₹ 10)]                       | 30   |                 |                 |
| Basic (₹)  |      | 3.23            | 2.28            |
| Diluted (₹)  |      | 3.23            | 2.28            |
| <b>Material Accounting policies</b>  | 2.2  |                 |                 |


The accompanying notes are an integral part of financial statements

As per our report of even date attached

**For B S R & Co. LLP**

Chartered Accountants

Firm Registration number : 101248W/W - 100022



Siddhartha Sharma

Partner

Membership number: 118756

**For and on behalf of the Board of Directors of**  
**Manipal Hospitals Private Limited**



Sameer Agarwal

Director

DIN: 07554053

Dr. H. Sudarshan Ballal

Director

DIN: 01195055



Khadija G Vahora

Company Secretary

Membership number: A37266

Place : Bengaluru

Date : May 27, 2025

Place : Bengaluru

Date : May 27, 2025

Manipal Hospitals Private Limited  
Statement of Changes in Equity for the year ended March 31, 2025

(a) Equity share capital\*

|   | Nos.           | (₹ in crores) |
|---|----------------|---------------|
| Equity shares of ₹. 10 each, issued, subscribed and fully paid-up |                |               |
| Balance as at April 01, 2023                                      | 1,02,52,97,268 | 1,025.30      |
| Change in equity share capital during the year                    | -              | -             |
| Balance as at March 31, 2024                                      | 1,02,52,97,268 | 1,025.30      |
| Change in equity share capital during the year                    | -              | -             |
| Balance as at March 31, 2025                                      | 1,02,52,97,268 | 1,025.30      |

\* Also, refer note 12

(b) Other equity\*\*

|                               | Reserves and Surplus |                   |   |  | Total other equity |
|-------------------------------|----------------------|-------------------|---|--|--------------------|
|                               | Securities premium   | Retained earnings | Amalgamation adjustment deficit account | Re-measurement gain/(loss) on defined benefit plan |                    |
| Balance as at April 01, 2023  | 246.89               | (526.52)          | (59.11)                                 | 0.52   | (338.22)           |
| Profit for the year           | -                    | 233.97            | -                                       | -  | 233.97             |
| OCI for the year (net of tax) | -                    | -                 | -                                       | (0.62)   | (0.62)             |
| Balance as at March 31, 2024  | 246.89               | (292.55)          | (59.11)                                 | (0.10)   | (104.87)           |
| Profit for the year           | -                    | 331.22            | -                                       | -  | 331.22             |
| OCI for the year (net of tax) | -                    | -                 | -                                       | (1.02)   | (1.02)             |
| Balance as at March 31, 2025  | 246.89               | 38.67             | (59.11)                                 | (1.12)   | 225.33             |

\*\* Also, refer note 13

Note : There are no changes in the accounting policies or prior period events during the current year or previous year.

Below is the nature and purpose of each reserve:


- Securities premium** - Securities premium is used to record the premium received on issue of shares.
- Re-measurement gain/(loss) on defined benefit plan** - Represents remeasurement gains / (losses) on defined benefit plans (net of tax).
- Retained earnings** - Retained earnings comprises of prior and current period's undistributed earnings after tax.
- Amalgamation adjustment deficit account** - It represents excess of consideration over carrying value of net assets (including reserves) in case of common control business combination. When there is a surplus in the Statement of profit and loss, this debit can be adjusted against that surplus.

Material accounting policies (refer note 2.2)

The accompanying notes are an integral part of financial statements


As per our report of even date attached

For B S R & Co. LLP  
Chartered Accountants  
Firm Registration number : 101248W/W - 100022



Siddhartha Sharma  
Partner  
Membership number: 118756

For and on behalf of the Board of Directors of  
Manipal Hospitals Private Limited



Sameer Agarwal  
Director  
DIN: 07554053



Dr. H. Sudarshan Ballal  
Director  
DIN: 01195055



Khadija G Vahora  
Company Secretary  
Membership number: A37266

Place : Bengaluru  
Date : May 27, 2025

Place : Bengaluru  
Date : May 27, 2025

Manipal Hospitals Private Limited  
Statement of Cash flow for the year ended

|   | (₹ in crores)   |                 |
|---|-----------------|-----------------|
|   | March 31, 2025  | March 31, 2024  |
| <b>A. Cash flows from operating activities</b>  |                 |                 |
| Profit before tax   | 445.54          | 316.23          |
| <b>Adjustments for:</b>   |                 |                 |
| Depreciation and amortisation expense   | 125.63          | 105.48          |
| Bad debts/ advances written off   | 16.07           | 12.58           |
| Loss /(Gain) allowance on trade receivables (net)                                     | 4.76            | (0.64)          |
| Loss allowance on other receivables (net)   | 0.10            | -               |
| Profit on sale of investments in mutual funds (net)                                   | (3.48)          | (11.35)         |
| Profit on sale of property, plant and equipment (net)                                 | (0.78)          | (2.37)          |
| Fair value gain on financial instruments at FVTPL                                     | (13.57)         | (2.26)          |
| Finance income  | (6.10)          | (12.84)         |
| Finance costs   | 107.03          | 114.99          |
| <b>Operating profit before working capital changes</b>                                | <b>675.20</b>   | <b>519.82</b>   |
| <b>Movements in working capital :</b>   |                 |                 |
| Change in trade receivables   | (45.99)         | (19.85)         |
| Change in loans   | (0.06)          | -               |
| Change in other assets  | 0.02            | 1.32            |
| Change in inventories   | (4.10)          | 0.43            |
| Change in other financial assets  | (0.29)          | 0.98            |
| Change in trade payables  | (85.77)         | 14.26           |
| Change in provisions  | (7.29)          | 2.44            |
| Change in other liabilities   | 3.17            | (0.65)          |
| Change in other financial liabilities   | 0.02            | 0.12            |
| Cash generated from operations  | <b>534.91</b>   | <b>518.87</b>   |
| Income tax paid (net)   | (67.42)         | (109.90)        |
| <b>Net cash generated from operating activities</b>                                   | <b>467.49</b>   | <b>408.97</b>   |
| <b>B. Cash flow from investing activities</b>   |                 |                 |
| Acquisition of property, plant and equipment and intangible assets                    | (98.26)         | (86.45)         |
| Proceeds from sale of property, plant and equipment                                   | 1.73            | 0.77            |
| Acquisition of subsidiary (refer note 5.1)  | -               | (654.53)        |
| Investment in other entities  | (0.02)          | (1.16)          |
| Loans given to related parties  | (314.90)        | (33.46)         |
| Loans repaid by related parties   | 335.95          | 259.80          |
| Investment made in bank deposits (having original maturity of more than three months) | (1.44)          | (1.41)          |
| Maturity of bank deposits (having original maturity of more than three months)        | -               | 14.96           |
| Proceeds from the sale of investments in mutual funds                                 | 993.26          | 1,372.83        |
| Purchase of investments in mutual funds   | (1,317.58)      | (1,212.47)      |
| Interest received   | 6.09            | 21.99           |
| <b>Net cash used in investing activities</b>  | <b>(395.17)</b> | <b>(319.13)</b> |
| <b>C. Cash flow from financing activities</b>   |                 |                 |
| Proceeds of long-term borrowings  | 94.24           | 108.76          |
| Repayment of long-term borrowings   | (54.46)         | (56.63)         |
| Proceeds of borrowings for purchase of capital asset                                  | 0.45            | 1.68            |
| Repayment of borrowings for purchase of capital asset                                 | (0.32)          | (0.32)          |
| Interest and processing charges paid  | (35.79)         | (37.66)         |
| Interest paid on loan for purchase of capital asset                                   | (0.16)          | (0.11)          |
| Payment of lease obligations  | (11.72)         | (8.17)          |
| Interest paid on lease  | (60.29)         | (57.22)         |
| <b>Net cash used in financing activities</b>  | <b>(68.05)</b>  | <b>(49.67)</b>  |
| <b>Net increase in cash and cash equivalents</b>                                      | <b>4.27</b>     | <b>40.17</b>    |
| Cash and cash equivalents at the beginning of the year                                | 60.94           | 20.77           |
| <b>Cash and cash equivalents at the end of the year (refer note 10.3)</b>             | <b>65.21</b>    | <b>60.94</b>    |
| <b>Components of cash and cash equivalents for the purpose of cash flow statement</b> |                 |                 |
| Cash on hand  | 1.37            | 0.92            |
| With banks - on current accounts  | 33.84           | 50.02           |
| - deposits with original maturity of less than three months                           | 30.00           | 10.00           |
| <b>Total cash and cash equivalents</b>  | <b>65.21</b>    | <b>60.94</b>    |

Material Accounting policies

2.2

Refer Note 40 for Reconciliation of movement of liabilities to cash flows arising from financing activities.


The above Cash flow statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard-7, "Statement of Cash Flows".

The accompanying notes are an integral part of financial statements


As per our report of even date attached


For BSR & Co. LLP


Chartered Accountants  
Firm Registration number : 101248W/W - 100022

  
Siddhartha Sharma  
Partner  
Membership number: 118756

For and on behalf of the Board of Directors of  
Manipal Hospitals Private Limited

  
Sameer Agarwal  
Director  
DIN: 07554053

  
H. Sudarshan Ballal  
Director  
DIN: 01195055

  
K.G. Vahora  
Khadija G Vahora  
Company Secretary  
Membership number: A37266

**1 Corporate information**

Manipal Hospitals Private Limited ("the Company") was established in the year 2003 and commissioned its first operating hospital in the year 2005. The Company is a private limited company incorporated under the provisions of the Companies Act of India. The registered office of the Company is located at The Annexe, #98/2, Rustam Bagh Road, HAL Airport Road, Bengaluru, 560017. The Company operates through various Hospitals/Clinics providing Healthcare services in India.

**2.1 Basis of preparation of the financial statements**

**(a) Statement of compliance**

The financial statements of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as per the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, notified under section 133 of the Companies Act, 2013 ('Act') and other relevant provisions of the Act.

The financial statements were approved for issue by the Company's Board of Directors on May 27, 2025

Details of the material accounting policies are included in Note 2.2

**(b) Functional and presentation currency**

These financial statements are presented in Indian Rupees (₹), which is also the Company's functional currency. All amounts are in Indian Rupees (₹) crores except share data and per share data, unless otherwise stated

**(c) Basis of measurement**

The financial statements have been prepared on accrual and going concern basis and the historical cost basis except for the following items:

| Items  | Measurement   |
|--|---|
| Certain financial assets and liabilities (Refer note 35) | Fair value  |
| Net defined asset / liability                            | Fair value of plan asset less present value of defined benefit obligation |

**(d) Use of estimates and judgments**

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

**Judgments, assumptions and estimation uncertainties**

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is included in the following notes:

**Judgements:-**

- Note 14.2 - Leases and lease classification
- Note 15 and 19- Provisions
- Note 16 - Income taxes including deferred tax
- Note 6 and 32 - Provision for Income tax and other contingencies

**Estimates:-**

- Note 2.2 (c), (d) and (g) - useful life of property, plant and equipment, intangible assets and right of use assets
- Note 5.1, 5.2, 10.2, 10.5, 10.6 - Impairment of financial assets and Investment in subsidiaries
- Note 26, 34 - Employee benefits expense, wages and bonus; key actuarial assumptions
- Note 35 - Financial instruments

**(e) Measurement of fair values**

The Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values is included in the note 35 – financial instruments.

**2.2 Summary of material accounting policies**

**(a) Investment in subsidiaries**

A subsidiary is an entity that is controlled by another entity. The investments in subsidiaries are carried at cost as per IND AS 27. Investment accounted for at cost is accounted for in accordance with IND AS 105 when they are classified as held for sale and Investment carried at cost is tested for impairment as per IND AS 36. On disposal of investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

**(b) Current versus non-current classification**

The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in the normal operating cycle.
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.



A liability is treated as current when:

- It is expected to be settled in the normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.



(c) **Property plant and equipment**

Property, plant and equipment including capital work in progress is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, import duties, cost of replacing part of the plant and equipment, borrowing costs if the recognition criteria are met and directly attributable cost of bringing the asset to its location and condition necessary for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in statement of profit and loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is derecognised.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the company and the cost of the item can be measured reliably.

Property, plant and equipment under installation or construction as at the balance sheet date is shown as capital work-in-progress and the related advances are shown as under Non current assets.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

| <u>Category of assets</u>             | <u>Useful life estimated by management</u> | <u>Useful life as per Schedule II</u> |
|---------------------------------------|--|---------------------------------------|
| Building                              | 23 - 30 years                              | 30 years                              |
| Leasehold improvements                | Lease term                                 | NA                                    |
| Equipment's                           | 13 years                                   | 10 - 15 years                         |
| Electrical installations              | 7 years                                    | 10 years                              |
| Furniture and fixtures                | 7 years                                    | 10 years                              |
| Other fixtures (included in Building) | 2 years                                    | 10 years                              |
| Computers                             | 3 years                                    | 3 - 6 years                           |
| Vehicles                              | 3-7 years                                  | 6 - 10 years                          |

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (up to) the date on which asset is ready for use (disposed of).

Second hand assets are depreciated over the estimated useful life as per technical estimates.

Leasehold land/Leasehold improvements/Leasehold Building are depreciated over the primary lease period or useful life, whichever is shorter, on a straight-line basis.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

The management has estimated, supported by technical assessment, the useful life of the category of assets, which are lower than those indicated in Schedule II to the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used.

(d) **Intangible assets**

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in statement of profit and loss as incurred.

A summary of amortization policies applied to the Company's intangible assets is as below:

| <u>Category of assets</u>       | <u>Useful life estimated by management</u> |
|---------------------------------|--|
| Computer software - application | 3-5 years                                  |
| Computer software - generic     | 1 year                                     |

(e) **Impairment of non-financial assets**

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long term growth rate is calculated and applied to project future cash flows till perpetuity.



For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs.

Impairment losses of continuing operations, including impairment of inventories, are recognised in the statement of profit and loss.

For all assets, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit and loss.

(f) **Borrowing Costs**

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.



(g) **Leases**

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

**Company as a lessee**

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any re-measurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. Right of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments, residual value guarantees, exercise price of a purchase option where the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently re-measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and re-measuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in statement of profit and loss.

The Company has elected not to apply the requirements of Ind AS 116 Leases to short term leases of all assets that have a lock in lease term of 12 months or less, except where it anticipates renewals and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

(h) **Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

**Financial assets**

**Initial recognition and measurement**

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price determined under Ind AS 115. Refer to the accounting policies in section (i) Revenue from contracts with customers.

In order for a financial asset to be classified and measured at amortised cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Company's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortised cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows while financial assets classified and measured at fair value through OCI are held within a business model with the objective of both holding to collect contractual cash flows and selling.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

**Subsequent measurement**

For purposes of subsequent measurement, financial assets are classified in four categories:

- i) Financial assets at amortised cost (debt instruments)
- ii) Financial assets at fair value through other comprehensive income (FVTOCI) with recycling of cumulative gains and losses (debt instruments)
- iii) Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments)
- iv) Financial assets at fair value through profit or loss

**Financial assets at amortised cost (debt instruments)**

A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. The Company's financial assets at amortised cost includes trade receivables. For more information on receivables, refer to Note 10.2.

**Financial assets at fair value through profit or loss**

Financial assets at fair value through profit or loss are carried in the balance sheet at fair value with net changes in fair value recognised in the statement of profit and loss.

**Derecognition**

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- i) The rights to receive cash flows from the asset have expired, or
- ii) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.



#### Impairment of financial assets

The Company recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

For trade receivables and other financial assets, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

The Company considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

#### Financial liabilities

##### Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and financial guarantee contracts.

##### Subsequent measurement

For purposes of subsequent measurement, financial liabilities are classified in two categories:

- Financial liabilities at fair value through profit or loss
- Financial liabilities at amortised cost (loans and borrowings)

##### Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.

Gains or losses on liabilities held for trading are recognised in the profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ losses are not subsequently transferred to P&L. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the statement of profit and loss. The Company has not designated any financial liability as at fair value through profit or loss.

##### Financial liabilities at amortised cost (Loans and borrowings)

This is the category most relevant to the Company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings.

##### Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

##### Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

#### (i) Inventories

Inventories of pharmacy items and medical consumables are valued at lower of cost or net realizable value. The comparison of cost and net realizable value is made on an item by item basis. Cost of these inventories comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location after adjusting for Goods and Services Tax (GST) wherever applicable, applying the first in first out basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs to be incurred to make the sale. Adequate provision is made for slow moving, non-moving and expired inventory, as determined necessary.

#### (j) Non-current assets held for sale

Non-current assets are classified as held for sale if it is highly probable that they will be recovered primarily through sale rather than through continuing use. Such assets, are generally measured at the lower of their carrying amount and fair value less costs to sell.

Non-current assets classified as held-for-sale are presented separately from the other assets in the balance sheet.



(k) Total income

(i) Revenue recognition

Revenue from contracts with customers is recognised as per Ind AS 115, "Revenue from contract with customers", when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, taking into consideration defined terms of payment and excluding taxes or duties collected on behalf of the government.

*Disaggregation of revenue*

The Company disaggregates revenue into revenue from rendering hospital services, pharmacy sales and other operating income. The Company believes that this disaggregation best depicts how the nature, amount, timing and uncertainty of Company's revenues and cash flows are affected by industry, market and other economic factors.

*Operating Income*

Revenue from Hospital services is recognised as and when the services are performed, unless significant future uncertainties exists, while revenue from sale of pharmacy items is recognised when the control of the goods or services to the buyer, usually on delivery of the goods. The Company assesses the distinct performance obligations in the contract and measures to at an amount that reflects the consideration it expects to receive, net of Goods and Services Tax and adjusted for discounts and concessions.

**Contract balances**

*Trade receivables*

Unbilled revenue represents the Company's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in section (i) Financial instruments – initial recognition and subsequent measurement.

*Contract liabilities*

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration from the customer. If a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Company performs its obligation under the contract.

(ii) Other income

*Interest Income*

For all debt instruments measured at amortised cost, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension) but does not consider the expected credit losses. Interest income is included in finance income in the statement of profit or loss.

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "finance income" in the statement of profit and loss.

(l) Foreign currencies

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The Company's financial statements are presented in INR, which is also the Company's functional and presentation currency.

*Transactions and balances*

Foreign currency transactions are recorded on initial recognition in the functional currency using the exchange rate prevailing at the date of the transaction. However, for practical reasons, the Company uses an average rate if the average approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on the settlement or translation of monetary items are recognised in the statement of profit and loss.

(m) Retirement and other employee benefits

*Defined contribution plan*

Retirement benefit in the form of Provident Fund and Pension Fund are defined contribution schemes. The Company recognizes contribution payable to the schemes as an expense, when an employee renders the related service. The Company has no obligation, other than the contribution payable to the fund.

*Defined benefit plan- gratuity*

The Company operates a defined benefit plan for its employees for gratuity. The costs of providing benefits under this plan is determined on the basis of actuarial valuation at each year end using the projected unit credit method.

Remeasurements, comprising of actuarial gains and losses, excluding amounts included in net interest on the net defined benefit liability (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to the statement of profit and loss in subsequent periods.

Past service costs are recognised in the statement of profit and loss on the earlier of :

- The date of the plan amendment or curtailment and
- The date that the Company recognises related restructuring costs

Interest is calculated by applying the discount rate to the defined benefit liability. The Company recognises the following changes in the defined benefit obligation as an expense in the statement of profit and loss:

- (i) Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements and
- (ii) Interest expense

*Other long-term employee benefits - compensated absences*

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. The Company presents the entire leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement beyond 12 months after the reporting date.



**(n) Taxes***Current income tax*

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities in accordance with the Income Tax Act, 1961 enacted in India. The tax rates and tax laws used to compute the amounts are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

*Deferred tax*

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences except:

- where deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside the statement of profit or loss is recognised outside the statement of profit or loss (either in OCI or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and to the same taxation authority.

**(o) Earnings Per Share (EPS)**

Basic EPS amounts are calculated by dividing the net profit/(loss) for the year attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit/(loss) for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the period adjusted for treasury shares held. Diluted earnings per share is computed using the weighted-average number of equity and dilutive equivalent shares outstanding during the period, using the treasury stock method for options and warrants, except where the results would be antidilutive.

**(p) Provisions**

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit or loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

*Decommissioning liability*

The Company records a provision for decommissioning costs to dismantle and remove the leasehold improvements from the leased premises. Decommissioning costs are provided at the present value of expected costs to settle the obligation using estimated cash flows and are recognised as part of the cost of the particular asset. The cash flows are discounted at a current pre-tax rate that reflects the risks specific to the decommissioning liability. The unwinding of the discount is expensed as incurred and recognised in the statement of profit and loss as a finance cost. The estimated future costs of decommissioning are reviewed annually and adjusted as appropriate. Changes in the estimated future costs or in the discount rate applied are added to or deducted from the cost of the asset.

*Onerous contracts*

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

**(q) Contingent liabilities**


A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements unless the possibility of an outflow of resources embodying economic benefits is remote.

Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

**(r) Cash and cash equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.



(s) Segment accounting policies

Operating segment are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM"). The Board of Directors of the Company has been identified as the Chief Operating Decision Maker. (refer note 38 on segment reporting).

(t) Corporate Social Responsibility (CSR) expenditure

CSR expenditure as per provisions of section 135 of Companies Act, 2013 read with The Companies (Corporate Social Responsibility Policy) Rules, 2014, is charged to the statement of profit and loss as an expense as and when incurred.

(u) Cash flow statement

Cash flows are reported using the indirect method, whereby net profit/ (loss) before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated. Bank overdrafts are classified as part of cash and cash equivalent, as they form an integral part of an entity's cash management.

(v) Share capital

Equity shares

Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

(w) New and amended standards

(i) Ind AS 117 Insurance Contracts

The Ministry of corporate Affairs (MCA) notified the Ind AS 117, Insurance Contracts, vide notification dated August 12, 2024, under the Companies (Indian Accounting Standards) Amendment Rules, 2024, which is effective from annual reporting periods beginning on or after April 01, 2024.

Ind AS 117 Insurance Contracts is a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. Ind AS 117 replaces Ind AS 104 Insurance Contracts. Ind AS 117 applies to all types of insurance contracts, regardless of the type of entities that issue them as well as to certain guarantees and financial instruments with discretionary participation features; a few scope exceptions will apply. Ind AS 117 is based on a general model, supplemented by:

- A specific adaptation for contracts with direct participation features (the variable fee approach)
- A simplified approach (the premium allocation approach) mainly for short-duration contracts

The application of Ind AS 117 had no impact on the financial statements as the Company has not entered any contracts in the nature of insurance contracts covered under Ind AS 117.

(ii) Amendment to Ind AS 116 Leases – Lease Liability in a Sale and Leaseback

The MCA notified the Companies (Indian Accounting Standards) Second Amendment Rules, 2024, which amend Ind AS 116, Leases, with respect to Lease Liability in a Sale and Leaseback.

The amendment specifies the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains.

The amendment is effective for annual reporting periods beginning on or after April 01, 2024 and must be applied retrospectively to sale and leaseback transactions entered into after the date of initial application of Ind AS 116.

The amendment does not have a material impact on the financial statements.


(x) Standards issued but not yet effective

(i) Amendment to Ind AS 21 The Effects of Changes in Foreign Exchange Rates

On May 07, 2025, The Ministry of Corporate Affairs notified the Companies (Indian Accounting Standards) Amendment Rules, 2025, which amend Ind AS 21 The Effects of Changes in Foreign Exchange Rates, to specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows.

The amendments are effective for annual reporting periods beginning on or after 1 April 2025. When applying the amendments, an entity cannot restate comparative information.

The amendments are not expected to have a material impact on the Company's financial statements.





3.1 Property, plant and equipment

|                        | Freehold land | Leasehold land # | Leasehold Improvements | Buildings | Plant and equipment | Facility and office equipment | Furniture and fixtures | Computer equipment | Vehicles | Electrical installation and equipment | Total    |
|------------------------|---------------|------------------|------------------------|-----------|---------------------|-------------------------------|------------------------|--------------------|----------|---------------------------------------|----------|
| (₹ in crores)          |               |                  |                        |           |                     |                               |                        |                    |          |                                       |          |
| <b>Cost</b>            |               |                  |                        |           |                     |                               |                        |                    |          |                                       |          |
| At April 01, 2023      | 70.34         | 18.63            | 145.37                 | 369.73    | 465.57              | 121.98                        | 42.94                  | 53.02              | 1.55     | 107.26                                | 1,396.39 |
| Additions              | -             | -                | 2.05                   | 3.51      | 44.89               | 0.18                          | 3.58                   | 9.88               | 2.38     | 5.41                                  | 71.88    |
| Disposals/ adjustments | 2.13          | -                | -                      | (0.01)    | (7.13)              | (2.03)                        | (0.93)                 | (1.53)             | (0.57)   | (0.02)                                | (10.09)  |
| At March 31, 2024      | 72.47         | 18.63            | 147.42                 | 373.23    | 503.33              | 120.13                        | 45.59                  | 61.37              | 3.36     | 112.65                                | 1,458.18 |
| Additions              | -             | -                | 7.10                   | 4.45      | 70.08               | -                             | 5.74                   | 11.34              | 1.31     | 8.49                                  | 108.51   |
| Disposals/ adjustments | -             | -                | (0.07)                 | (2.40)    | (8.08)              | (7.67)                        | (3.23)                 | (4.12)             | (0.21)   | (0.09)                                | (25.87)  |
| At March 31, 2025      | 72.47         | 18.63            | 154.45                 | 375.28    | 565.33              | 112.46                        | 48.10                  | 68.59              | 4.46     | 121.05                                | 1,540.82 |
| <b>Depreciation</b>    |               |                  |                        |           |                     |                               |                        |                    |          |                                       |          |
| At April 01, 2023      | 26.98         | -                | 6.25                   | 150.09    | 241.93              | 109.52                        | 37.56                  | 38.14              | 0.91     | 60.51                                 | 671.89   |
| Charge for the year    | -             | -                | 5.92                   | 10.73     | 29.30               | 4.66                          | 2.87                   | 8.06               | 0.31     | 9.72                                  | 71.57    |
| Disposals/ adjustments | -             | -                | -                      | (0.01)    | (6.77)              | (2.01)                        | (0.91)                 | (1.53)             | (0.44)   | (0.02)                                | (11.69)  |
| At March 31, 2024      | 26.98         | -                | 12.17                  | 160.81    | 264.46              | 112.17                        | 39.52                  | 44.67              | 0.78     | 70.21                                 | 731.77   |
| Charge for the year    | -             | -                | 6.67                   | 11.51     | 33.44               | 4.40                          | 3.17                   | 10.87              | 0.58     | 10.36                                 | 81.00    |
| Disposals/ adjustments | -             | -                | (0.07)                 | (2.23)    | (7.39)              | (7.66)                        | (3.23)                 | (4.06)             | (0.20)   | (0.08)                                | (24.92)  |
| At March 31, 2025      | 26.98         | -                | 18.77                  | 170.09    | 290.51              | 108.91                        | 39.46                  | 51.48              | 1.16     | 80.49                                 | 787.85   |
| <b>Net book value</b>  |               |                  |                        |           |                     |                               |                        |                    |          |                                       |          |
| At March 31, 2024      | 45.49         | 18.63            | 135.25                 | 212.42    | 238.87              | 7.96                          | 6.07                   | 16.70              | 2.58     | 42.44                                 | 726.41   |
| At March 31, 2025      | 45.49         | 18.63            | 135.68                 | 205.19    | 274.82              | 3.55                          | 8.64                   | 17.11              | 3.30     | 40.56                                 | 752.97   |

\* Refer note 14.1 for details of Property, plant and equipment provided as security for borrowings.

Notes:

# Leasehold land represents lease term ranging from 999 years to perpetuity.



3.2 Capital Work-in-progress

|   | (₹ in crores) |
|---|---------------|
|   | Total         |
| Cost  |               |
| At April 01, 2023                             | 11.34         |
| Additions during the year                     | 70.20         |
| Transferred to Property, plant and equipment  | (71.88)       |
| At March 31, 2024                             | 9.66          |
| Additions during the year                     | 112.18        |
| Transferred to Property, plant and equipments | (108.51)      |
| At March 31, 2025                             | 13.33         |

Capital work in progress ageing schedule

As at March 31, 2025

| Particulars          | Amount in CWIP for a period of |           |           |                   |   | Total |
|----------------------|--------------------------------|-----------|-----------|-------------------|---|-------|
|                      | Less than 1 year               | 1-2 years | 2-3 years | More than 3 years |   |       |
| Projects in progress | 13.33                          | -         | -         | -                 | - | 13.33 |
| Total                | 13.33                          | -         | -         | -                 | - | 13.33 |

There are no material capital work-in-progress for which the completion is overdue or has exceeded its cost compared to its original budget.

As at March 31, 2024

| Particulars          | Amount in CWIP for a period of |           |           |                   |   | Total |
|----------------------|--------------------------------|-----------|-----------|-------------------|---|-------|
|                      | Less than 1 year               | 1-2 years | 2-3 years | More than 3 years |   |       |
| Projects in progress | 5.87                           | 3.49      | 0.30      | -                 | - | 9.66  |
| Total                | 5.87                           | 3.49      | 0.30      | -                 | - | 9.66  |

There are no material capital work-in-progress for which the completion is overdue or has exceeded its cost compared to its original budget.

\* Refer note 14.1 for details of Capital Work-in-progress provided as security for borrowings

4.1 Right of use assets

(₹ in crores)

|                          | Right-of-use assets         |            |          |           |                          | Total  |
|--------------------------|-----------------------------|------------|----------|-----------|--------------------------|--------|
|                          | Leasehold land & building * | Equipments | Vehicles | Computers | Electrical installations |        |
| Cost                     |                             |            |          |           |                          |        |
| At April 01, 2023        | 469.40                      | 16.20      | 0.68     | 10.33     | -                        | 496.61 |
| Additions                | 28.94                       | -          | -        | 5.43      | -                        | 34.37  |
| Disposals or Adjustments | -                           | (4.14)     | -        | -         | -                        | (4.14) |
| At March 31, 2024        | 498.34                      | 12.06      | 0.68     | 15.76     | -                        | 526.84 |
| Additions                | 3.09                        | -          | -        | -         | 15.67                    | 18.76  |
| Disposals                | (2.35)                      | -          | -        | -         | -                        | (2.35) |
| At March 31, 2025        | 499.08                      | 12.06      | 0.68     | 15.76     | 15.67                    | 543.25 |
| Depreciation             |                             |            |          |           |                          |        |
| At April 01, 2023        | 85.49                       | 9.12       | 0.68     | 5.92      | -                        | 101.21 |
| Charge for the year      | 19.07                       | 0.93       | -        | 1.66      | -                        | 21.66  |
| Disposals                | -                           | -          | -        | -         | -                        | -      |
| At March 31, 2024        | 104.56                      | 10.05      | 0.68     | 7.58      | -                        | 122.87 |
| Charge for the year      | 21.47                       | 0.50       | -        | 5.56      | 1.67                     | 29.20  |
| Disposals                | (1.95)                      | -          | -        | -         | -                        | (1.95) |
| At March 31, 2025        | 124.08                      | 10.55      | 0.68     | 13.14     | 1.67                     | 150.12 |
| Net book value           |                             |            |          |           |                          |        |
| At March 31, 2024        | 393.78                      | 2.01       | -        | 8.18      | -                        | 403.97 |
| At March 31, 2025        | 375.00                      | 1.51       | -        | 2.62      | 14.00                    | 393.13 |

\* Refer note 14.1 for details of assets provided as security for borrowings



4.2 Intangible assets

|                       | (₹ in crores)            |
|-----------------------|--------------------------|
|                       | <u>Intangible assets</u> |
|                       | <u>Computer software</u> |
| <b>Cost</b>           |                          |
| At April 01, 2023     | 46.06                    |
| Additions             | 34.36                    |
| Disposals             | -                        |
| At March 31, 2024     | <u>80.42</u>             |
| Additions             | 4.92                     |
| Disposals             | (0.02)                   |
| At March 31, 2025     | <u>85.32</u>             |
| <b>Amortisation</b>   |                          |
| At April 01, 2023     | 29.86                    |
| Charge for the year   | 12.25                    |
| Disposals             | -                        |
| At March 31, 2024     | <u>42.11</u>             |
| Charge for the year   | 15.43                    |
| Disposals             | (0.02)                   |
| At March 31, 2025     | <u>57.52</u>             |
| <b>Net book value</b> |                          |
| At March 31, 2024     | <u>38.31</u>             |
| At March 31, 2025     | <u>27.80</u>             |

\* Refer note 14.1 for details of Intangible assets provided as security for borrowings.



5 Non-current financial assets

5.1 Investments

|   | (₹ in crores)  |                |                |                |
|---|----------------|----------------|----------------|----------------|
|   | No of units    |                | Amounts        |                |
|   | March 31, 2025 | March 31, 2024 | March 31, 2025 | March 31, 2024 |
| Investments carried at cost (unquoted)  |                |                |                |                |
| <b>A) Investment in equity shares of subsidiary company</b>   |                |                |                |                |
| Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited)<br>[shares of ₹ 10 each fully paid-up, refer note 5.1.1]                  | 5,71,12,194    | 5,71,12,194    | 396.00         | 396.00         |
| (A)   |                |                | <u>396.00</u>  | <u>396.00</u>  |
| <b>B) Investment in Compulsory convertible debentures ("CCD") of subsidiary company</b>   |                |                |                |                |
| MHEIPL<br>[refer note 5.1.1]  | 850            | 850            | 314.57         | 314.57         |
| (B)   |                |                | <u>314.57</u>  | <u>314.57</u>  |
| <b>Aggregate value of unquoted investments carried at cost (A+B)</b>  |                |                | <u>710.57</u>  | <u>710.57</u>  |
| <b>Investments at fair value through Profit and Loss</b>  |                |                |                |                |
| <b>Investments in other companies</b>   |                |                |                |                |
| O2 Renewable Energy X Private Limited   |                |                |                |                |
| -Equity shares of ₹ 10 each fully paid up   | 1,15,900       | 1,15,900       | 0.12           | 0.12           |
| -Compulsory convertible debentures of ₹ 1000 each   | 10,424         | 10,424         | 1.04           | 1.04           |
| [Refer note 5.1.2]  |                |                |                |                |
| Atria Wind Power (Basavana Bagewadi) Private Limited  |                |                |                |                |
| -Equity shares of ₹ 100 each fully paid up  | 1,000          | -              | 0.02           | -              |
| [Refer note 5.1.3]  |                |                | <u>1.18</u>    | <u>1.16</u>    |
| (C)   |                |                |                |                |
| <b>Investments in mutual funds (quoted)*</b>  | (D)            |                | 18.65          | 14.95          |
| Information about the company's exposure to credit and market risks, and fair value measurement, is included in Note 35 & 36<br>* Refer note 14.1 for details of Investments provided as security for borrowings. |                |                |                |                |
| <b>Aggregate value of investments carried at fair value through Profit and Loss (C+D)</b>   |                |                | <u>19.83</u>   | <u>16.11</u>   |
| <b>Aggregate value of investments (A+B+C+D)</b>   |                |                | <u>730.40</u>  | <u>726.68</u>  |
| Aggregate value of investments  |                |                | 730.40         | 726.68         |

5.1.1 On September 20, 2023 the Company along with its affiliates, acquired 5,71,12,194 equity shares and 850 compulsorily convertible debentures of Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) from existing shareholders aggregating to 84.07% shareholding of Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) on a fully diluted basis.

5.1.2 On October 23, 2023, the Company subscribed to 1,15,900 equity shares and 10,424 Series B compulsory convertible debentures of O2 Renewable Energy X Private Limited as captive power consumer.

5.1.3 On January 16, 2025 the Company has invested an amount of ₹ 0.02 crores in Atria Wind Power (Basavana Bagewadi) Private Limited by purchasing 1000 equity shares as captive power consumer.

5.2 Loans (Unsecured considered good unless otherwise stated)

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Inter Corporate Deposit given to related parties (refer note 5.2.1)  | 12.76          | 34.92          |
| Less: Interest accrued on inter corporate deposits to related parties - disclosed under other non-current financial assets | (0.35)         | (1.46)         |
|  | <u>12.41</u>   | <u>33.46</u>   |

5.2.1 Term of the loan as given below:

| Name of the loanee              | Rate of Interest | Repayment         | Secured/ unsecured | (₹ in crores)  |  |
|---------------------------------|------------------|-------------------|--------------------|----------------|--|
|                                 |                  |                   |                    | March 31, 2025 | Movement during the year<br>March 31, 2024 |
| MHEIPL                          |                  |                   |                    |                |  |
| Inter Corporate Deposit ("ICD") | 9.00%            | Thirty-Six months | Unsecured          | 12.41          | (21.05)                                    |

The intercorporate deposit has been made available to MHEIPL for the purpose of meeting its general corporate requirements.

Provisions of section 186 of the Companies Act, 2013, except sub section (1), are not applicable, as the Company is engaged in the business of providing infrastructural facilities as specified in Schedule VI of the Companies Act, 2013.

5.3 Other financial assets (Secured considered good unless otherwise stated)

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Margin money deposit with banks (refer note 5.3.1)   | 0.60           | 0.50           |
| Deposits with banks due to mature after twelve months from the reporting date (refer note 5.3.2) | 7.23           | 6.78           |
| Interest accrued on ICD to related parties (refer note 5.3.3)                                    | 0.35           | 1.46           |
| Security deposits  | 17.42          | 15.95          |
|  | <u>25.60</u>   | <u>24.69</u>   |

(5.3.1) Margin money deposits with a carrying amount of ₹ 0.60 crores (March 31, 2024: ₹ 0.50 crores) are provided as bank guarantee.

(5.3.2) It includes Debt Service Reserve Account maintained by the company with Banks amounting to ₹ 7.23 crores (March 31, 2024: ₹ 6.74 crores)


(5.3.3) Receivable from related parties (refer note 31)

6 Income tax assets (net)

|   | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| Income tax assets (net of provision for income tax) | 11.25          | 58.64          |
|   | <u>11.25</u>   | <u>58.64</u>   |

7 Other non-current assets (Unsecured considered good unless otherwise stated)

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Capital advances                                 |                |                |
| Considered good                                  | 0.37           | 2.20           |
| Considered doubtful                              | 17.88          | 17.88          |
|  | 18.25          | 20.08          |
| Less: Provision for doubtful capital advances    | (17.88)        | (17.88)        |
|  | 0.37           | 2.20           |
| Prepaid expenses                                 | 0.43           | 0.57           |
| Balances with statutory / government authorities | 17.64          | -              |
| Defined benefit plan assets (Refer note 34)      | 1.68           | -              |
|  | <u>20.12</u>   | <u>2.77</u>    |



| 8 Assets held for sale | (₹ in crores)  |                |
|------------------------|----------------|----------------|
|                        | March 31, 2025 | March 31, 2024 |
| Land                   | 6.50           | 6.50           |
|                        | <b>6.50</b>    | <b>6.50</b>    |

(8.1) Land held for sale pertains to land situated at Meerut ₹ 6.5 crores (March 31, 2024: ₹ 6.5 crores)

(8.2) As of March 31, 2025, the Company is actively responding to evolving market conditions and ongoing infrastructure developments in and around Meerut. Efforts to market the land are ongoing, with the aim of achieving optimal realisation through a potential sale.

| 9 Inventories (valued at lower of cost and net realizable value) | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Pharmacy items   | 13.43          | 13.01          |
| Medical consumables  | 17.94          | 14.26          |
|  | <b>31.37</b>   | <b>27.27</b>   |

Refer note 14.1 for details of Inventories provided as security for borrowings.

| 10 Current financial assets                       | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| 10.1 Investments                                  |                |                |
| Investments at fair value through Profit and Loss |                |                |
| Investments in mutual funds (quoted)*             | 399.07         | 61.40          |
|   | <b>399.07</b>  | <b>61.40</b>   |

\*Information about the company's exposure to credit and market risks, and fair value measurement, is included in Note 35 & 36

\* Refer note 14.1 for details of Investments provided as security for borrowings.

| 10.2 Trade receivables (Unsecured considered good unless otherwise stated) | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Considered good  | 109.47         | 84.31          |
| Credit impaired  | 19.28          | 14.52          |
|  | 128.75         | 98.83          |
| Less: Loss allowance on trade receivables                                  | (19.28)        | (14.52)        |
|  | <b>109.47</b>  | <b>84.31</b>   |

Refer note 14.1 for details of Trade receivables provided as security for borrowings.

(10.2.1) There are no trade receivables which have significant increase in credit risk

(10.2.2) Ageing for trade receivables and unbilled revenue due from the due date for each of the category is as follows:

As at 31 March 2025

| Particulars   | Outstanding for following periods from due date of payment |                    |                   |             |             |                   | Total         |
|---|--|--------------------|-------------------|-------------|-------------|-------------------|---------------|
|   | Not due*   | Less than 6 Months | 6 months - 1 year | 1-2 years   | 2-3 years   | More than 3 years |               |
| Undisputed Trade Receivables - considered good                                | 70.09  | 38.93              | 0.45              | -           | -           | -                 | 109.47        |
| Undisputed Trade Receivables - which have significant increase in credit risk | -  | -                  | -                 | -           | -           | -                 | -             |
| Undisputed Trade receivable - credit impaired                                 | -  | 9.72               | 7.18              | 2.32        | 0.06        | -                 | 19.28         |
| Disputed Trade receivables - considered good                                  | -  | -                  | -                 | -           | -           | -                 | -             |
| Disputed Trade receivables - which have significant increase in credit risk   | -  | -                  | -                 | -           | -           | -                 | -             |
| Disputed Trade receivables - credit impaired                                  | -  | -                  | -                 | -           | -           | -                 | -             |
| <b>Total</b>  | <b>70.09</b>   | <b>48.65</b>       | <b>7.63</b>       | <b>2.32</b> | <b>0.06</b> | <b>-</b>          | <b>128.75</b> |

\* includes unbilled revenue of ₹ 14.23 crores as considered good

As at 31 March 2024

| Particulars   | Outstanding for following periods from due date of payment |                    |                   |             |           |                   | Total        |
|---|--|--------------------|-------------------|-------------|-----------|-------------------|--------------|
|   | Not due*   | Less than 6 Months | 6 months - 1 year | 1-2 years   | 2-3 years | More than 3 years |              |
| Undisputed Trade Receivables - considered good                                | 49.35  | 34.26              | 0.70              | -           | -         | -                 | 84.31        |
| Undisputed Trade Receivables - which have significant increase in credit risk | -  | -                  | -                 | -           | -         | -                 | -            |
| Undisputed Trade receivable - credit impaired                                 | -  | 4.25               | 9.65              | 0.62        | -         | -                 | 14.52        |
| Disputed Trade receivables - considered good                                  | -  | -                  | -                 | -           | -         | -                 | -            |
| Disputed Trade receivables - which have significant increase in credit risk   | -  | -                  | -                 | -           | -         | -                 | -            |
| Disputed Trade receivables - credit impaired                                  | -  | -                  | -                 | -           | -         | -                 | -            |
| <b>Total</b>  | <b>49.35</b>   | <b>38.51</b>       | <b>10.35</b>      | <b>0.62</b> | <b>-</b>  | <b>-</b>          | <b>98.83</b> |

\* includes unbilled revenue of ₹ 9.53 crores as considered good.

| 10.3 Cash and cash equivalents                              | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| Balances with banks:  |                |                |
| - On current accounts                                       | 33.84          | 50.02          |
| - Deposits with original maturity of less than three months | 30.00          | 10.00          |
| Cash on hand  | 1.37           | 0.92           |
| <b>Total cash and cash equivalents</b>                      | <b>65.21</b>   | <b>60.94</b>   |

| 10.4 Bank balances other than cash and cash equivalents                  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Bank deposits due to mature within twelve months from the reporting date | -              | 7.90           |
|  | -              | <b>7.90</b>    |



10.5 Loans (Unsecured considered good unless otherwise stated)

Loans to employees

| (₹ in crores)  |                |
|----------------|----------------|
| March 31, 2025 | March 31, 2024 |
| 0.26           | 0.20           |
| <b>0.26</b>    | <b>0.20</b>    |

10.6 Other financial assets (Unsecured considered good unless otherwise stated)

Margin money deposit with banks  
Interest accrued on fixed deposits  
Other receivables #  
    Considered good  
    Considered doubtful  
    Less: Loss allowance on Other receivable  
    **Net other receivables**

Security deposits

# includes receivables from related parties (refer note 31)

\* Refer note 14.1 for details of Other financial assets provided as security for borrowings

| (₹ in crores)  |                |
|----------------|----------------|
| March 31, 2025 | March 31, 2024 |
| 11.10          | 2.31           |
| 0.42           | 0.53           |
| 0.60           | 0.64           |
| 0.28           | 0.18           |
| (0.28)         | (0.18)         |
| 0.60           | 0.64           |
| 0.40           | 0.41           |
| <b>12.52</b>   | <b>3.89</b>    |


11 Other assets (Unsecured considered good unless otherwise stated)

Prepaid expenses  
Advances to suppliers  
Balance with government authorities

\* Refer note 14.1 for details of Other assets provided as security for borrowings.

| (₹ in crores)  |                |
|----------------|----------------|
| March 31, 2025 | March 31, 2024 |
| 5.52           | 5.81           |
| 3.68           | 4.97           |
| 1.35           | 18.97          |
| <b>10.55</b>   | <b>29.75</b>   |

(This space has been intentionally left blank)



12 Equity Share capital

|  | (₹ in crores)   |                 |
|--|-----------------|-----------------|
|  | March 31, 2025  | March 31, 2024  |
| <b>12.1 Authorised shares (Nos.)</b><br>1,104,950,000 (March 31, 2024: 1,104,950,000) Equity shares of ₹ 10/- each                           | 1,104.95        | 1,104.95        |
| <b>12.2 Issued, subscribed and fully paid-up shares (Nos.)</b><br>1,025,297,268 (March 31, 2024: 1,025,297,268) Equity Shares of ₹ 10/- each | 1,025.30        | 1,025.30        |
| <b>Total issued, subscribed and fully paid-up share capital</b>  | <b>1,025.30</b> | <b>1,025.30</b> |

12.3 Reconciliation of the number of equity shares outstanding at the beginning and at the end of the reporting year:

|                               | March 31, 2025        |                 | March 31, 2024        |                 |
|-------------------------------|-----------------------|-----------------|-----------------------|-----------------|
|                               | Nos.                  | (₹ in crores)   | Nos.                  | (₹ in crores)   |
| At the beginning of the year  | 1,02,52,97,268        | 1,025.30        | 1,02,52,97,268        | 1,025.30        |
| Add : Issued during the year  | -                     | -               | -                     | -               |
| <b>At the end of the year</b> | <b>1,02,52,97,268</b> | <b>1,025.30</b> | <b>1,02,52,97,268</b> | <b>1,025.30</b> |

12.4 Terms/rights attached to equity shares

The Company has only one class of equity shares having par value of ₹ 10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The final dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. During the year, the Company has not declared any dividend.

In the event of liquidation of the Company, the holders of equity shares would be entitled to receive remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to number of equity shares held by shareholders.

12.5 Shares held by holding company

|  | March 31, 2025 |               | March 31, 2024 |               |
|--|----------------|---------------|----------------|---------------|
|  | Nos.           | (₹ in crores) | Nos.           | (₹ in crores) |
| Manipal Health Enterprises Private Limited ("MHEPL") * | 1,02,52,97,268 | 1,025.30      | 1,02,52,97,268 | 1,025.30      |

\*Includes 10,000 (March 31, 2024: 10,000) equity shares of ₹ 10 each held by nominee director on behalf of the holding company.

12.6 Details of shareholders holding more than 5% shares in the company:

|  | March 31, 2025   |                        | March 31, 2024   |                        |
|--|------------------|------------------------|------------------|------------------------|
|  | Number of shares | % holding in the class | Number of shares | % holding in the class |
| <b>Equity shares of ₹ 10 each fully paid</b><br>Manipal Health Enterprises Private Limited | 1,02,52,97,268   | 100.00%                | 1,02,52,97,268   | 100.00%                |

As per the records of the Company, including its register of shareholders/ members and other declaration received from shareholders regarding beneficial interest, the above shareholding represent both legal and beneficial ownership of shares

12.7 Details of shareholding by the promoter of the company

| As at March 31, 2025                       |  |                        |                                      |                   |                          |
|--|--|------------------------|--------------------------------------|-------------------|--------------------------|
| Promoter Name                              | No. of shares at the beginning of the year | Change during the year | No. of shares at the end of the year | % of Total Shares | % change during the year |
| Manipal Health Enterprises Private Limited | 1,02,52,97,268                             | -                      | 1,02,52,97,268                       | 100.00%           | 0.00%                    |
|  | <b>1,02,52,97,268</b>                      | <b>-</b>               | <b>1,02,52,97,268</b>                | <b>100.00%</b>    | <b>0.00%</b>             |
| As at March 31, 2024                       |  |                        |                                      |                   |                          |
| Promoter Name                              | No. of shares at the beginning of the year | Change during the year | No. of shares at the end of the year | % of Total Shares | % change during the year |
| Manipal Health Enterprises Private Limited | 1,02,52,97,268                             | -                      | 1,02,52,97,268                       | 100.00%           | 0.00%                    |
|  | <b>1,02,52,97,268</b>                      | <b>-</b>               | <b>1,02,52,97,268</b>                | <b>100.00%</b>    | <b>0.00%</b>             |

12.8 There have been no issue of bonus shares, buy back of shares, issue of shares for consideration other than cash for the period of five years immediately preceding the balance sheet date.

12.9 As at March 31, 2025 and March 31, 2024, the Company does not have any shares reserved for issue under options and contracts or commitments for the sale of shares.

13 Other equity

|  | (₹ in crores)  |                 |
|--|----------------|-----------------|
|  | March 31, 2025 | March 31, 2024  |
| <b>13.1 Securities premium</b><br>Balance at the beginning of the year                                 | 246.89         | 246.89          |
| Add: Addition during the year  | -              | -               |
| <b>Balance at the end of the year</b>  | <b>246.89</b>  | <b>246.89</b>   |
| <b>13.2 Re-measurement gain/(loss) on defined benefit plan</b><br>Balance at the beginning of the year | (0.10)         | 0.52            |
| OCI for the year (net of tax)  | (1.02)         | (0.62)          |
| <b>Balance at the end of the year</b>  | <b>(1.12)</b>  | <b>(0.10)</b>   |
| <b>13.3 Retained earnings</b><br>Balance at the beginning of the year                                  | (292.55)       | (526.52)        |
| Add: Profit for the year   | 331.22         | 233.97          |
| <b>Balance at the end of the year</b>  | <b>38.67</b>   | <b>(292.55)</b> |
| <b>13.4 Amalgamation adjustment deficit account</b><br>Balance at the beginning of the year            | (59.11)        | (59.11)         |
| Add: Addition during the year  | -              | -               |
| <b>Balance at the end of the year</b>  | <b>(59.11)</b> | <b>(59.11)</b>  |
| <b>Total of other equity</b>   | <b>225.33</b>  | <b>(104.87)</b> |



14 Non-current financial liabilities

14.1 Borrowings (secured unless other-wise stated)

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| <b>Borrowings</b>  |                |                |
| Term loan from banks (refer note 14.1.1 & 14.1.2)                                  | 388.15         | 427.24         |
| Term loan from financial institutions (refer note 14.1.1 & 14.1.2)                 | 79.32          | -              |
| Loan for purchase of capital asset (refer note 14.1.3 & 14.1.4)                    | 1.99           | 1.86           |
| <b>(A)</b>   | <b>469.46</b>  | <b>429.10</b>  |
| <b>Less: Current maturities - disclosed under the head 'short term borrowings'</b> |                |                |
| Term loan from banks   | 60.37          | 54.37          |
| Term loan from financial institutions  | 0.70           | -              |
| Loan for purchase of capital asset   | 0.40           | 0.31           |
| <b>(B)</b>   | <b>61.47</b>   | <b>54.68</b>   |
| <b>Non- Current Borrowings</b>   | <b>(A-B)</b>   | <b>374.42</b>  |

14.1.1 Details of Principal outstanding, rate of interest and repayment terms for term loans from banks and financial institutions

As at March 31, 2025

| Particulars                                | Interest Rate | Frequency | Number of structured installements | Year of Maturity  | Principal Outstanding (net of transaction cost) |
|--|---------------|-----------|------------------------------------|-------------------|---|
| Secured Term loan (Bank 1)                 | 8.19%         | Quarterly | Upto 38 Installements              | June 30, 2028     | 69.58   |
| Secured Term loan (Bank 2)                 | 8.25%         | Quarterly | Upto 36 Installements              | June 30, 2028     | 54.48   |
| Secured Term loan (Bank 3)                 | 8.15%         | Quarterly | Upto 48 Installements              | June 30, 2034     | 204.09  |
| Secured Term loan (Bank 4)                 | 8.25%         | Quarterly | Upto 40 Installements              | March 31, 2036    | 60.00   |
| Secured Term loan (Financial instituion 1) | 8.25%         | Quarterly | Upto 80 Installements              | December 31, 2044 | 79.32   |

As at March 31, 2024

| Particulars                | Interest Rate | Frequency | Number of structured installements | Year of Maturity | Principal Outstanding (net of transaction cost) |
|----------------------------|---------------|-----------|------------------------------------|------------------|---|
| Secured Term loan (Bank 1) | 8.65%         | Quarterly | Upto 38 Installements              | June 30, 2028    | 91.97   |
| Secured Term loan (Bank 2) | 8.72%         | Quarterly | Upto 36 Installements              | June 30, 2028    | 71.78   |
| Secured Term loan (Bank 3) | 8.40%         | Quarterly | Upto 48 Installements              | June 30, 2034    | 218.32  |
| Secured Term loan (Bank 4) | 8.50%         | Quarterly | Upto 40 Installements              | March 31, 2036   | 45.17   |

14.1.2 The terms and conditions of all the term loans from banks and financial institutions are similar and are as follows:

During the year ended March 31, 2025, the Company entered into facility agreement with its lenders and offered consolidated security as below:-

- A first ranking pari passu security interest over all movable fixed assets and current assets of the Company along with MHEPL, MHEIPL, Manipal Hospitals (Dwarka) Private Limited ("MHDPL") and Manipal Hospitals (Bengaluru) Private Limited ("MHBPL") including but not limited to movable plant and machinery, machinery spares, tools and accessories, furniture, fixtures, intangible assets (including goodwill, trademarks and patents) and all other movable properties of whatsoever nature (both present and future) (other than any debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to the facilities) as per the facility agreement;
- A first ranking pari passu security interest over specific immovable properties of the company, MHEPL, MHEIPL and MHDPL
- A first ranking pari passu security interest, by way of hypothecation, over all leasehold improvements of all immovable properties and excluded properties.
- Exclusive security interest over the debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to such facility)

During the year ended March 31, 2024, the terms and conditions of all the term loans from banks are as follows:

- A first pari-passu charge over all movable, immovable fixed assets and current assets of the Company along with MHEPL, MHDPL, MHBPL & MHEIPL other than fixed Deposits and mutual funds kept as DSRA & immovable properties mentioned as excluded properties in facility agreements.
- Exclusive security interest over the amount in the Debt Service Reserve Accounts required to be maintained by the company
- Irrevocable and unconditional corporate guarantee by MHEPL, MHBPL & MHDPL. Subsequent to the acquisition of MHEIPL during the year March 31, 2024, MHEIPL assets are also offered to lenders for security.
- Non disposal undertaking by MHEPL in respect of each shareholding aggregating up to 100% (One hundred percent) in the company.

14.1.3 Details of Principal outstanding, rate of interest and repayment terms for loan for purchase of capital asset

|                                     | March 31, 2025   | March 31, 2024  |
|-------------------------------------|------------------|-----------------|
| Principal outstanding (₹ in crores) | 1.99             | 1.86            |
| Rate of interest                    | (8.35% to 9.15%) | (8.6% to 9.40%) |
| Year of repayment                   | 2027 to 2031     | 2027 to 2030    |

14.1.4 The Company obtained vehicle under financing arrangements from Bank and secured against such vehicle.



14.2 Lease liabilities

|                                     | (₹ in crores)  |                |
|-------------------------------------|----------------|----------------|
|                                     | March 31, 2025 | March 31, 2024 |
| Opening balance                     | 569.51         | 537.45         |
| Add: New leases during the year     | 18.70          | 33.40          |
| Add: Interest accrued               | 70.11          | 66.28          |
| Less: Interest paid                 | (60.29)        | (57.22)        |
| Less: Lease paid                    | (11.72)        | (8.17)         |
| Less: Lease termination/adjustments | (0.46)         | (2.23)         |
|                                     | <b>585.85</b>  | <b>569.51</b>  |
| Non-current                         | 574.16         | 558.02         |
| Current                             | 11.69          | 11.49          |

14.2.1 Notes

The Company has taken on lease certain land and building for hospital operations, hostels for staff, equipment's, office spaces and vehicles for use in the course of its business.

Refer notes 2.2(g) in relation to accounting policy for leases.

Refer note 4.1 for depreciation charge for right-of-use assets by class of underlying asset and additions to right-of-use assets and the carrying amount of right-of-use assets at the end of the reporting period by class of underlying asset.

Refer note 29.1 in relation to short term leases and leases of low-value assets accounted for applying paragraph 6 of Ind AS 116.

Refer note 36C disclosure on maturity analysis of lease payments

Refer note 40 disclosure on cash outflows for leases liabilities

15 Provisions

|   | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| Non-current                                     |                |                |
| Provision for gratuity (refer note 7 & note 34) | -              | 7.71           |
|   | -              | <b>7.71</b>    |

16 Income Tax

The major components of income tax expense for the year ended March 31, 2025 and March 31, 2024 are:

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| <b>Statement of Profit and loss:</b>                           |                |                |
| <b>Current income tax:</b>                                     |                |                |
| Current year income tax charge                                 | 119.59         | 92.64          |
| Adjustment of tax relating to earlier years                    | (3.48)         | 0.25           |
|  | <b>116.11</b>  | <b>92.89</b>   |
| <b>Deferred tax :</b>  |                |                |
| Origination and reversal of temporary differences              | (1.79)         | (10.63)        |
| <b>Tax expense reported in the statement of profit or loss</b> | <b>114.32</b>  | <b>82.26</b>   |

OCI section

Tax on net loss on remeasurement of defined benefit plan

**Income tax credit reported in OCI**

|               |               |
|---------------|---------------|
| (0.33)        | (0.21)        |
| <b>(0.33)</b> | <b>(0.21)</b> |

**Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate:**

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Profit before tax  | 445.54         | 316.23         |
| Statutory income tax rate of 25.17% (March 31, 2024: 25.17%) | 112.13         | 79.59          |
| Tax effect of non-deductible expenses                        | 1.18           | 6.28           |
| Impact of statutory tax rate changes on capital gains        | 4.22           | -              |
| Tax adjustment pertaining to earlier years                   | (3.48)         | -              |
| Others   | 0.27           | (3.61)         |
|  | <b>114.32</b>  | <b>82.26</b>   |

Deferred tax

|   | (₹ in crores)               |                |  |                |
|---|-----------------------------|----------------|--|----------------|
|   | Recognised in balance sheet |                | Recognised in profit and loss and other comprehensive income |                |
|   | March 31, 2025              | March 31, 2024 | March 31, 2025   | March 31, 2024 |
| Property plant equipment and Intangible assets:   | (150.17)                    | (150.77)       | (0.60)   | (0.73)         |
| Impact of difference between tax depreciation as per Income Tax Act, 1961 over depreciation/ amortization as per Companies Act, 2013.   |                             |                |  |                |
| Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis * # | 155.86                      | 152.14         | (3.72)   | (9.13)         |
| Allowance for bad and doubtful debts  | 4.92                        | 3.65           | (1.27)   | 0.09           |
| Fair valuation of investments in mutual funds   | (4.08)                      | (0.70)         | 3.38   | (0.37)         |
| Others  | 10.03                       | 10.12          | 0.09   | (0.70)         |
| <b>Deferred tax expense (credit)</b>  |                             |                | <b>(2.12)</b>  | <b>(10.84)</b> |
| <b>Net deferred tax Assets</b>  | <b>16.56</b>                | <b>14.44</b>   |  |                |


\* Includes items under 43B such as Leave encashment, gratuity, bonus.

# Gratuity amount routed through Other Comprehensive Income pertaining to remeasurement of defined benefit plan

Reflected in the balance sheet as follows:

|                                  | (₹ in crores)  |                |
|----------------------------------|----------------|----------------|
|                                  | March 31, 2025 | March 31, 2024 |
| Deferred tax assets              | 170.81         | 165.91         |
| Deferred tax liabilities         | (154.25)       | (151.47)       |
| <b>Deferred tax Assets (net)</b> | <b>16.56</b>   | <b>14.44</b>   |

The Company has elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019.



17 Current financial liabilities

17.1 Short term borrowings

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Term loan from banks (refer note 14.1.1 & 14.1.2)                  | 60.37          | 54.37          |
| Term loan from financial institutions (refer note 14.1.1 & 14.1.2) | 0.70           | -              |
| Loan for purchase of capital asset (refer note 14.1.3 & 14.1.4)    | 0.40           | 0.31           |
|  | <b>61.47</b>   | <b>54.68</b>   |

17.2 Trade payables

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Trade payables   |                |                |
| - total outstanding dues of micro enterprises and small enterprises*                     | 6.11           | 5.40           |
| - total outstanding dues of creditors other than micro enterprises and small enterprises | 268.89         | 352.26         |
|  | <b>275.00</b>  | <b>357.66</b>  |

\*Also refer note 43

(17.2.1) For details relating to payable to related parties refer note 31

(17.2.2) There were no disputed dues from Micro enterprises and small enterprises and other creditors.

As at 31 March 2025

| Particulars  | Outstanding for following periods from due date of payment |                  |             |             |                   | Total         |
|--|--|------------------|-------------|-------------|-------------------|---------------|
|  | Not due<br>(Including provision<br>for expense)            | Less than 1 year | 1-2 years   | 2-3 years   | More than 3 years |               |
| Total outstanding dues of micro enterprises and small enterprises                      | 5.82   | 0.29             | -           | -           | -                 | 6.11          |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 226.73   | 33.19            | 2.82        | 3.85        | 2.30              | 268.89        |
| Disputed dues of micro enterprises and small enterprises                               | -  | -                | -           | -           | -                 | -             |
| Disputed dues of creditors other than micro enterprises and small enterprises          | -  | -                | -           | -           | -                 | -             |
| <b>Total</b>   | <b>232.55</b>  | <b>33.48</b>     | <b>2.82</b> | <b>3.85</b> | <b>2.30</b>       | <b>275.00</b> |

As at 31 March 2024

| Particulars  | Outstanding for following periods from due date of payment |                  |             |             |                   | Total         |
|--|--|------------------|-------------|-------------|-------------------|---------------|
|  | Not due<br>(Including provision<br>for expense)            | Less than 1 year | 1-2 years   | 2-3 years   | More than 3 years |               |
| Total outstanding dues of micro enterprises and small enterprises                      | 4.88   | 0.52             | -           | -           | -                 | 5.40          |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 317.68   | 27.02            | 5.71        | 1.33        | 0.52              | 352.26        |
| Disputed dues of micro enterprises and small enterprises                               | -  | -                | -           | -           | -                 | -             |
| Disputed dues of creditors other than micro enterprises and small enterprises          | -  | -                | -           | -           | -                 | -             |
| <b>Total</b>   | <b>322.56</b>  | <b>27.54</b>     | <b>5.71</b> | <b>1.33</b> | <b>0.52</b>       | <b>357.66</b> |

18 Other financial liabilities

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Interest accrued but not due on borrowings * | 0.06           | 0.09           |
| Capital creditors **                         | 20.67          | 7.11           |
| Sundry deposits                              | 0.33           | 0.31           |
| Retention money                              | 1.50           | 1.05           |
|  | <b>22.56</b>   | <b>8.56</b>    |

\* The details of interest rates, repayment and other terms are disclosed under note 14.1

\*\* As at March 31, 2025, outstanding amount of ₹ 1.20 crores (March 31, 2024: ₹ 0.39 crores) is due to micro and small enterprises. There are no interest due or outstanding on the same. There were no amounts paid to micro and small enterprises beyond the due date during the current and the previous years.

19 Provisions


|                                    | (₹ in crores)  |                |
|------------------------------------|----------------|----------------|
|                                    | March 31, 2025 | March 31, 2024 |
| <b>Current</b>                     |                |                |
| Provision for compensated absences | 13.07          | 10.76          |
|                                    | <b>13.07</b>   | <b>10.76</b>   |

20 Other current liabilities


|   | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| Statutory dues                                    | 10.86          | 8.87           |
| Advance received from customer [refer note 22(b)] | 9.31           | 8.12           |
|   | <b>20.17</b>   | <b>16.99</b>   |

21 Current tax liabilities (net)

|                               | (₹ in crores)  |                |
|-------------------------------|----------------|----------------|
|                               | March 31, 2025 | March 31, 2024 |
| Current tax liabilities (net) | 1.78           | 0.47           |
|                               | <b>1.78</b>    | <b>0.47</b>    |




|           |   | (₹ in crores)   |                 |
|-----------|---|-----------------|-----------------|
|           |   | March 31, 2025  | March 31, 2024  |
| <b>22</b> | <b>Revenue from operations</b>  |                 |                 |
|           | Hospital services   | 2,129.36        | 1,821.26        |
|           | Pharmacy sales  | 84.58           | 62.22           |
|           | Less: Discounts   | (76.91)         | (105.62)        |
|           | <b>Total (a)</b>  | <b>2,137.03</b> | <b>1,777.86</b> |
|           | <b>Other operating revenues</b>   |                 |                 |
|           | Rental income   | 2.33            | 1.82            |
|           | Parking charges   | 0.91            | 0.53            |
|           | Occupational health centre and ambulance service  | 10.52           | 2.59            |
|           | Others  | 2.96            | 5.01            |
|           | <b>Total (b)</b>  | <b>16.72</b>    | <b>9.95</b>     |
|           | <b>Total (a+b)</b>  | <b>2,153.75</b> | <b>1,787.81</b> |
| a)        | The revenue from contracts with customer at disaggregation is provided above.   |                 |                 |
| b)        | Changes in contract liabilities- Advance received from customers  |                 |                 |
|           |   | (₹ in crores)   |                 |
|           |   | March 31, 2025  | March 31, 2024  |
|           | <b>Balance at the beginning of the year</b>   | <b>8.12</b>     | <b>8.57</b>     |
|           | Less: Revenue recognised that was included in the balance at the beginning of the year (refer note 20)  | (8.12)          | (8.57)          |
|           | Add: Increase due to advance from patients received (refer note 20)   | 9.31            | 8.12            |
|           | <b>Balance at the end of the year</b>   | <b>9.31</b>     | <b>8.12</b>     |
|           | <b>Expected revenue recognition from remaining performance obligations:</b>   |                 |                 |
|           | - Within one year   | 9.31            | 8.12            |
| c)        | Contract balances   |                 |                 |
|           |   | (₹ in crores)   |                 |
|           |   | March 31, 2025  | March 31, 2024  |
|           | Receivables   |                 |                 |
|           | - Trade receivables (refer note 10.2)   | 109.47          | 84.31           |
|           | Contract liabilities  |                 |                 |
|           | - Advance received from customer (refer note 20)  | 9.31            | 8.12            |
|           | Trade receivable are non-interest bearing and are generally on a terms of 30 to 120 days.   |                 |                 |
|           | Contract liabilities relates to the advances received from the customers to deliver the hospital service. There is no significant changes in the contract liabilities during the year.  |                 |                 |
| d)        | The company's performance obligation is to provide the hospital service to patients, this is part of a contract that has an original expected duration of less than one year, hence the company has taken the practical expedient related to performance obligation disclosure as provided by Ind AS 115. |                 |                 |
| <b>23</b> | <b>Other income</b>   |                 |                 |
|           |   | (₹ in crores)   |                 |
|           |   | March 31, 2025  | March 31, 2024  |
|           | Profit on sale of investments in mutual funds (net)   | 3.48            | 11.35           |
|           | Fair value gain on financial instruments at FVTPL   | 13.57           | 2.26            |
|           | Profit on sale of property, plant and equipment (net)   | 0.78            | 2.37            |
|           | Interest income on income tax refund  | 1.43            | 1.26            |
|           |   | <b>19.26</b>    | <b>17.24</b>    |
| <b>24</b> | <b>Finance income</b>   |                 |                 |
|           |   | (₹ in crores)   |                 |
|           |   | March 31, 2025  | March 31, 2024  |
|           | Interest on inter corporate deposit *   | 3.82            | 10.74           |
|           | Interest income on financial assets at amortised cost   | 0.82            | 0.72            |
|           | Interest income on bank deposits  | 1.46            | 1.38            |
|           |   | <b>6.10</b>     | <b>12.84</b>    |
|           | * includes transactions with related parties (refer note 31)  |                 |                 |
| <b>25</b> | <b>Changes in inventories of medical consumables and pharmacy items</b>   |                 |                 |
|           |   | (₹ in crores)   |                 |
|           |   | March 31, 2025  | March 31, 2024  |
|           | <b>Pharmacy items</b>   |                 |                 |
|           | Inventory at the beginning of the year  | 13.01           | 11.74           |
|           | Less: Inventory at the end of the year  | (13.43)         | (13.01)         |
|           |   | (0.42)          | (1.27)          |
|           | <b>Other medical consumables</b>  |                 |                 |
|           | Inventory at the beginning of the year  | 14.26           | 15.96           |
|           | Less: Inventory at the end of the year  | (17.94)         | (14.26)         |
|           |   | (3.68)          | 1.70            |
|           |   | <b>(4.10)</b>   | <b>0.43</b>     |



**Manipal Hospitals Private Limited**  
**Notes to financial statements for the year ended March 31, 2025**

|             |   | (₹ in crores)  |                |
|-------------|---|----------------|----------------|
|             |   | March 31, 2025 | March 31, 2024 |
| <b>26</b>   | <b>Employee benefits expense *</b>  |                |                |
|             | Salaries, wages and bonus   | 216.90         | 180.14         |
|             | Contribution to provident and other funds (refer note 34)   | 14.27          | 12.40          |
|             | Gratuity expenses (refer note 34)   | 3.04           | 2.52           |
|             | Staff welfare expenses  | 6.76           | 14.65          |
|             |   | <b>240.97</b>  | <b>209.71</b>  |
|             | * includes transactions with related parties (refer note 31)  |                |                |
| <b>27</b>   | <b>Finance costs</b>  |                |                |
|             | Bank charges  | 9.86           | 8.71           |
|             | Interest  |                |                |
|             | - on bank loan  | 35.57          | 34.53          |
|             | - on defined benefit obligation (refer note 34)   | 0.54           | 0.46           |
|             | - on leases   | 70.11          | 66.28          |
|             | - on vehicle loan   | 0.16           | 0.11           |
|             | - on self-assessment tax  | 0.01           | 0.13           |
|             | - on others   | -              | 11.59          |
|             | Loan processing fees  |                |                |
|             | - on financial liabilities measured at amortised cost   | 0.64           | 1.89           |
|             | <b>Total finance costs</b>  | <b>107.03</b>  | <b>114.99</b>  |
|             |   | <b>116.89</b>  | <b>123.70</b>  |
| <b>28</b>   | <b>Depreciation and amortisation expense</b>  |                |                |
|             | Depreciation of property, plant and equipment (refer note 3.1)  | 80.99          | 71.57          |
|             | Depreciation of right of use assets (refer note 4.1)  | 29.21          | 21.66          |
|             | Amortisation of intangible assets (refer note 4.2)  | 15.43          | 12.25          |
|             |   | <b>125.63</b>  | <b>105.48</b>  |
| <b>29</b>   | <b>Other expenses</b>   |                |                |
|             | Doctors professional fees   | 515.05         | 438.84         |
|             | House keeping, including consumables  | 26.04          | 24.09          |
|             | Power and fuel and other utilities  | 35.07          | 35.34          |
|             | Security charges  | 13.38          | 12.06          |
|             | Rent (refer note 29.1)  | 22.18          | 19.24          |
|             | Contractual manpower  | 62.33          | 39.25          |
|             | Rates and taxes   | 3.09           | 19.02          |
|             | Insurance   | 3.98           | 2.93           |
|             | Repairs and maintenance   |                |                |
|             | - Buildings   | 1.59           | 2.16           |
|             | - Plant and machinery   | 19.06          | 17.94          |
|             | - Others **   | 36.14          | 25.10          |
|             | Corporate social responsibility (refer note 39)   | 4.59           | 2.45           |
|             | Advertising and sales promotion**   | 80.39          | 60.86          |
|             | Travelling and conveyance   | 8.16           | 6.08           |
|             | Communication costs   | 1.61           | 2.21           |
|             | Printing and stationery   | 6.59           | 6.57           |
|             | Legal and professional fees**   | 21.72          | 16.44          |
|             | Payment to auditors   | 0.89           | 1.06           |
|             | Bad debts/advances written off  | 16.07          | 12.58          |
|             | Loss allowance on trade receivables (net of reversals)  | 4.76           | (0.64)         |
|             | Loss allowance on other receivables (net of reversals)  | 0.10           | 0.00*          |
|             | Foreign exchange loss (net)   | 0.98           | 0.10           |
|             | Miscellaneous expenses  | 3.18           | 2.95           |
|             |   | <b>886.95</b>  | <b>746.63</b>  |
|             | * Represents value less than ₹. 0.01 crore  |                |                |
|             | ** includes transactions with related parties (refer note 31)   |                |                |
| <b>29.1</b> | Represents amounts incurred by the Company towards expenses relating to short-term leases, leases of low-value assets and ineligible GST on lease payments written off. Also refer note 2.2(g). |                |                |
| <b>29.2</b> | <b>Payment to auditors*</b>   |                |                |
|             | Audit fees  | 0.89           | 1.06           |
|             |   | <b>0.89</b>    | <b>1.06</b>    |
|             | *Amount inclusive of Goods and Service Tax (GST).   |                |                |



**30 Earnings per share (EPS)**

The following reflects the income and share data used in the basic and diluted EPS computations:

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Profit attributable to the equity shareholders for basic EPS | 331.22         | 233.97         |
| Weighted average number of equity shares                     | 1,02,52,97,268 | 1,02,52,97,268 |
| Earnings per share - Basic and diluted - ₹                   | 3.23           | 2.28           |

**31 Related party transactions**

(a) Names of related parties where control exists irrespective of whether transactions have occurred or not:

|                 |   |
|-----------------|---|
| Holding Company | - Manipal Health Enterprises Private Limited ('MHEPL')  |
| Subsidiary      | - Manipal Hospitals (East) India Private Limited ('MHEIPL') (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited ) (w.e.f September 20, 2023) |

(b) Names of other related parties as per Ind AS 24 with whom transactions have taken place during the year:

|   |   |
|---|---|
| Fellow subsidiaries   | - Manipal Hospitals (Dwarka) Private Limited ('MHDPL')<br>- Manipal Hospitals (Bengaluru) Private Limited ('MHBPL')<br>- Healthmap Diagnostics Private Limited                                  |
| Other related parties<br>(Enterprises under significant influence of ultimate holding company/holding company upto July 13, 2023)<br><br>(Enterprise over which Key management personnel ("KMP") of holding company has significant influence from July 13, 2023) | - Manipal Cigna Health Insurance Company Limited<br>- Manipal Foundation<br>- MEMG International India Private Ltd<br>- UNext Learning Private Limited<br>- Manipal Academy of Higher Education |

(c) Names of other related parties as per Ind AS 24 with whom transactions have not taken place during the year:


|                           |  |
|---------------------------|--|
| Key management personnel: | - Dr. H. Sudarshan Ballal, Director<br>- Mr. Karthik Rajagopal, Director<br>- Mr. Sameer Agarwal, Director |
|---------------------------|--|

(d) Names of additional related parties as per Companies Act, 2013:

|                        |                        |
|------------------------|------------------------|
| KMP: Company Secretary | - Ms. Khadija G Vahora |
|------------------------|------------------------|

**Transactions with the above related parties during the year ended:**

| Name of related party                          | Nature of transaction   | (₹ in crores)  |                |
|--|---|----------------|----------------|
|  |   | March 31, 2025 | March 31, 2024 |
| Remuneration to key management personnel (KMP) | Employee Benefits   | 0.20           | 0.11           |
| Manipal Health Enterprises Private Limited     | Hospital Services received                                      | 9.85           | 12.93          |
|  | Hospital Services rendered                                      | 2.28           | 1.56           |
|  | Purchase of medical pharmacies/consumables (net of returns)     | 1.80           | 1.67           |
|  | Sale of medical pharmacies/consumables (net of returns)         | 0.26           | 0.26           |
|  | Reimbursement of Expenses incurred on behalf of the company     | 225.23         | 206.78         |
|  | Recovery of expenses incurred on behalf of other company        | 3.16           | 17.71          |
|  | Amount received from related party                              | 20.00          | -              |
|  | Amount paid to related party                                    | 262.04         | 198.92         |
|  | Sale of asset   | -              | 0.06           |
| Manipal Academy of Higher Education            | Hospital Services rendered                                      | 1.11           | -              |
|  | Amount received from related party                              | 1.19           | -              |
| Manipal Cigna Health Insurance Company Limited | Insurance expenses  | 2.34           | 1.81           |
| Manipal Hospitals (Dwarka) Private Limited     | Interest Income on ICD  | -              | 9.12           |
|  | ICD repayment received the year                                 | -              | 259.80         |
|  | Interest Income received on ICD repayment                       | -              | 19.54          |
|  | Amount paid to related party                                    | -              | 0.08           |
|  | Amount received from related party                              | 0.11           | -              |
|  | Recovery of expenses incurred on behalf of the related party    | 0.13           | 0.08           |
| MEMG International India Private Ltd           | Reimbursement of expenses incurred on behalf of the Company     | 0.04           | 0.13           |
|  | Royalty charges (included under legal and professional expense) | 10.77          | 8.66           |
| Manipal Foundation                             | Corporate Social Responsibility Expenditure                     | 4.59           | 2.45           |



|  |  |                             |        |
|--|--|-----------------------------|--------|
| Manipal Hospitals (Bengaluru) Private Limited                | Purchase of Asset  | 0.04                        | 0.01   |
|  | Purchase of medical pharmacies/consumables (net of returns)  | 0.08                        | -      |
|  | Amount paid to related party   | 3.36                        | -      |
|  | Hospital Services rendered   | 1.37                        | -      |
|  | Hospital Services received   | 0.00                        | -      |
|  | Reimbursement of expenses incurred on behalf of the Related party  | 3.64                        | 3.14   |
|  | Recovery of expenses incurred on behalf of the related party   | 0.07                        | 1.88   |
|  | Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) | Investment in equity shares | -      |
| Investment in CCD  |  | -                           | 314.57 |
| ICD given during the year                                    |  | 314.90                      | -      |
| ICD repayment received the year                              |  | 335.95                      | -      |
| Interest Income received on ICD repayment                    |  | 4.54                        | -      |
| Interest Income on ICD                                       |  | 3.82                        | 1.62   |
| Purchase of medical pharmacies/consumables (net of returns)  |  | 0.11                        | -      |
| Sale of medical pharmacies/consumables (net of returns)      |  | 0.04                        | -      |
| Amount paid to related party                                 |  | 0.68                        | -      |
| Amount received from related party                           |  | 0.02                        | -      |
| Reimbursement of expenses incurred on behalf of the Company  |  | 0.29                        | -      |
| Recovery of expenses incurred on behalf of the related party |  | 0.59                        | -      |
| Hospital Services rendered                                   |  | 0.18                        | 0.05   |
| Hospital Services received                                   |  | 1.83                        | 0.09   |
| UNext Learning Private Limited                               | Hospital Services rendered   | 0.02                        | -      |
|  | Amount received from related party   | 0.01                        | -      |
| Healthmap Diagnostics Private Limited                        | Hospital services received   | 0.80                        | -      |

**Balances receivable from/payable to related parties are as follows:**



(₹ in crores)

| Name of related party  | Nature of balances      | March 31, 2025 | March 31, 2024 |
|--|-------------------------|----------------|----------------|
| Manipal Health Enterprises Private Limited   | Trade Payables          | 7.03           | 17.01          |
| ManipalCigna Health Insurance Company Limited  | Prepaid expenses        | -              | 1.78           |
|  | Advance to Suppliers    | 0.11           | -              |
| Manipal Foundation   | Trade Payables          | 0.07           | -              |
| Manipal Hospitals (Dwarka) Private Limited   | Other receivables       | 0.01           | 0.03           |
| MEMG International India Private Limited   | Trade Payables          | 4.32           | 1.78           |
| Manipal Academy of Higher education  | Other receivables       | 0.18           | -              |
| Manipal Hospitals (Bengaluru) Private Limited  | Other receivables       | -              | 0.02           |
|  | Trade Payables          | 0.56           | 1.26           |
| Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited and AMRI Hospitals Limited) | ICD                     | 12.41          | 33.46          |
|  | Interest accrued on ICD | 0.35           | 1.46           |
|  | Trade Payables          | 0.84           | 0.04           |
| UNext Learning Private Limited   | Other receivables       | 0.02           | -              |
| Healthmap Diagnostics Private Limited  | Trade payables          | 0.01           | -              |

**Terms and conditions of transactions with related parties**

The sales/purchases, income/expenses, loans from/to related parties are made on terms equivalent to those that prevail in arm's length transactions. During the current and previous years, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

(This space has been intentionally left blank)



32 Contingent liabilities

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| (A) Claims against the Company not acknowledged as debts |                |                |
| i) Patient Compensation                                  | 2.41           | 3.45           |
| ii) Indirect Tax   |                |                |
| Goods and Service Tax                                    | 17.26          | 10.83          |
| Finance Act, 1994  | 11.40          | 11.40          |
| (B) Guarantees   |                |                |
| i) Bank guarantees                                       | 0.21           | 0.43           |
|  | <b>31.28</b>   | <b>26.11</b>   |

(i) Patient Compensation

There are certain claims made against the Company in respect of patient compensation. The cases are pending with various Consumer Disputes Redressal Commissions. Based, on the legal counsel's views, the management does not expect these claims to succeed. Accordingly, no provision for liability has been recognized in the financial statements.

The Company is confident that its position will be upheld for above litigations and accordingly no provision has been made in the Financial Statements.

(ii) Indirect Tax Demand

Goods and Service Tax

(a) The Company went in for Advance Ruling seeking clarification on chargeability of GST on activities performed by its employees at the Corporate office in the course of or in relation to employment viz., accounting, other administrative and IT system maintenance for its units located in states outside of the Karnataka. The Authority for Advance Ruling passed an order calling it as supply and hence chargeable to GST. Aggrieved by the order, the company appealed against the said order with the Appellate Authority of Advance Ruling (AAAR) which again passed the order in favour of Revenue. Aggrieved by the order passed by AAAR, the Company has filed a writ petition with the Hon'ble high court of Karnataka on April 26, 2019 to quash the said order. Fresh Interlocutory Applications, challenging the validity of constitution of AAR/AAAR was listed for hearing in April 2021. The matter was heard and the respondents (Union and State) were directed to file objections. Expected liability as on March 31, 2025 is ₹. 12.38 crores (As on March 31, 2024: ₹. 10.71 crores).

(b) During the year 2016-17, while filing TRAN-1- Transitional ITC for CENVAT Credit and Value added Tax (VAT) credit, the Company has inadvertently claimed SGST credit in TRANS-1 amounting to ₹.0.47 crores while there was no VAT credit available to be transitioned to Goods and Service Tax (GST). Upon realizing its mistake, the Company has voluntarily remitted back the same amount. Subsequently, the department issued notice for difference in credit claimed as per Tran 1 and VAT returns and has demanded interest of ₹. 0.07 crores and penalty of ₹. 0.05 crores as applicable under KGST Act. The Company has thereafter made payment of the interest in 2021. Considering the above fact, that the Company has already remitted the impugned amount even before the authorities identified along with the interest, the company believes it has a good case and the penalty imposed would be set aside.

(c) During the year ended March 31, 2025, the company has received an order issued by Joint Commissioner for the period March 2021 to September 2022, wherein GST demand of ₹. 2.38 crore and equal amount of penalty with interest is raised towards Non- Payment of GST on Supply of COVID-19 vaccines and its related vaccination charges. Aggrieved by the impugned order, subsequent to the year end, the Company has filed a Writ before Hon'ble High Court of Karnataka and obtained the stay.

Finance Act, 1994

(a) Commissioner, Central Tax (Audit-1, Commissionerate) has issued show cause notice no.54/2020-21 CTA-1/Commr. dtd. December 30, 2020 towards non-reversal of Cenvat credit/non-payment of Service Tax payable under provisions of Rule 6 of the Cenvat Credit Rules, 2004 in respect of exempted services for the period from October 1, 2014 to June 30, 2017 for an amount of ₹. 10.10 crores including interest and penalty. The Company has remitted the tax amount of ₹. 3.55 crores under protest and filed response to the notice before the Principal Commissioner/ Commissioner of Central Tax, East Commissionerate on February 26, 2021. The authorities vide OIO No. 57/2021 dt. November 30, 2021 confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company has filed the appeal with CESTAT on April 18, 2022

(b) Deputy Commissioner, Circle IV, Central Tax (Audit-1, Commissionerate) has issued show cause notice no.47/2020-21 CTA-1/Dy Commr. dtd. December 18, 2020 towards non-payment of Service Tax under reverse charge on services received from Director of the Company payable under Section 68(2) of the Finance Act, 1994 for an amount of ₹. 1.30 crores (March 31, 2024: ₹. 1.30 crores) including interest and penalty. The Company has filed its response to the show cause notice before the Deputy/Assistant Commissioner of Central Tax East division -5, Bangalore East Commissionerate on January 18, 2021. The authorities vide OIO No. 199/2022 dt. March 31, 2022 confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company has filed the appeal with Commissioner of Service Tax(Appeals) on June 16, 2022 and remitted the tax amount of ₹. 0.31 crores under protest.

Based on the discussions, the Company had with the tax experts, they are of the view that the Company has good case on merits and has higher probability of winning the above cases, both under GST and Finance Act. Accordingly, it has been disclosed as a contingent liability.

(iii) The Company along with MHEPL, MHBPL, MHDPL and MHEIPL have provided security to various lenders in the form of first ranking pari passu charge over Immovable properties including lease hold improvements, Movable Fixed Assets, Intangibles assets and Current Assets (as defined in the Facility Agreements) for the term loans amounting to ₹. 4,663.53 crore (March 31 2024: ₹. 3,883.13 crores) availed by the Company, MHEPL, MHBPL, MHDPL, HCMCT (Silo), MHEIPL and Manipal Hospitals Eastern India Private Limited ('MH Eastern')

Pending resolution of the respective proceedings, it is not practicable for the company to estimate the timings of cash outflows, if any, in respect of the above as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

33 Capital Commitments and other commitments

As at March 31, 2025, the company has a commitment towards purchase of capital asset of ₹. 73.67 crores (March, 31 2024: ₹. 61.90 crores)



34 Employee benefit plan

(i) Defined contribution plan:

Amount recognised and included in note 26, Contribution to provident and other funds in statement of profit and loss of ₹ 14.27 crores (March 31, 2024: ₹ 12.40 crores).

(ii) Defined benefit plan:

The Company has a defined benefit gratuity plan. Under this plan, every employees who are entitled as per the Gratuity Act, gets a gratuity on departure at 15 days of last drawn salary for each completed year of service. The gratuity plan is a funded plan and the Company makes contributions to funds maintained with an insurance company.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet.

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2023 |
| <b>a) Statement of profit and loss and other comprehensive income</b>                |                |                |
| <b>i) Net employee benefit expense recognized in the statement of profit or loss</b> |                |                |
| Current service cost   | 3.04           | 2.52           |
| Interest cost on benefit obligation  | 0.90           | 0.80           |
| Expected return on plan assets   | (0.36)         | (0.34)         |
| <b>Net benefit expense charged to statement of profit or loss</b>                    | <b>3.58</b>    | <b>2.98</b>    |
| <b>ii) Remeasurement</b>   |                |                |
| Actuarial changes arising from changes in:   |                |                |
| -Financial assumptions   | 0.75           | 0.38           |
| -Demographic assumptions   | 0.29           | -              |
| -Experience adjustments  | 0.43           | 0.49           |
| Return on plan assets excluding interest income                                      | (0.12)         | (0.04)         |
| <b>Total amount recognised in other comprehensive income</b>                         | <b>1.35</b>    | <b>0.83</b>    |
| <b>b) Balance Sheet</b>  |                |                |
| <b>Defined benefit obligation</b>  |                |                |
| Present value of funded defined benefit obligation                                   | 15.92          | 12.75          |
| Fair value of plan assets  | 17.60          | 5.04           |
| <b>Unfunded status</b>   | <b>(1.68)</b>  | <b>7.71</b>    |
| <b>Net defined benefit (asset)/liability</b>   |                |                |
| Non current  | (1.68)         | 7.71           |
| Current  | -              | -              |
| <b>Plan (asset)/liability</b>  | <b>(1.68)</b>  | <b>7.71</b>    |
| <b>c) Change in projected benefit obligations</b>                                    |                |                |
| Defined benefit obligation at the beginning of the year                              | 7.71           | 6.43           |
| Fair value of plan assets at the beginning of the year                               | 5.04           | 4.66           |
| Current service cost   | 3.04           | 2.52           |
| Interest cost  | 0.90           | 0.80           |
| Benefits paid  | (1.55)         | (2.53)         |
| Remeasurement of gain in other comprehensive income:                                 |                |                |
| Actuarial changes arising from changes in:   |                |                |
| -Financial assumptions   | 0.75           | 0.38           |
| -Demographic assumptions   | 0.29           | -              |
| -Experience adjustments  | 0.43           | 0.49           |
| Liabilities settled on account of intergroup transfer                                | (0.69)         | -              |
| Fair value of plan assets at the end of the year                                     | (17.60)        | (5.04)         |
| <b>Obligations at end of the year</b>  | <b>(1.68)</b>  | <b>7.71</b>    |
| <b>d) Movements in the fair value of plan assets are as follows</b>                  |                |                |
| Fair value of plan assets at the beginning of the year                               | 5.04           | 4.66           |
| Interest income  | 0.36           | 0.34           |
| Actuarial gain/(loss) on plan assets   | 0.12           | 0.04           |
| Contribution paid into the plan  | 13.63          | 2.53           |
| Benefits paid  | (1.55)         | (2.53)         |
| <b>Fair value of plan assets at the end of the year</b>                              | <b>17.60</b>   | <b>5.04</b>    |

**Defined plan asset**

Plan assets consist of assets held in a "long-term benefit fund" for the sole purpose of making future benefit payments when they fall due. Plan assets include qualifying insurance policies and are not quoted in the market.

The Company expects to pay ₹ 0.50 crore in contributions to its defined benefit plans in 2025-26

**e) The principal assumptions used in determining gratuity liability for the Company's plan are shown below:**

|                               |          |          |
|-------------------------------|----------|----------|
| Discount rate                 | 6.70%    | 7.20%    |
| Increase in compensation cost | 6.00%    | 6.00%    |
| Retirement Age                | 60 years | 60 years |

**Employee turnover**

| Age (Years)    |                | Age (Years)    |                |
|----------------|----------------|----------------|----------------|
| Rate (p.a.)    |                | Rate (p.a.)    |                |
| March 31, 2025 | March 31, 2025 | March 31, 2024 | March 31, 2024 |
| 21 - 30        | 24.63%         | 21 - 30        | 24.04%         |
| 31 - 34        | 10.17%         | 31 - 34        | 5.81%          |
| 35 - 44        | 8.34%          | 35 - 44        | 4.73%          |
| 45 - 50        | 2.87%          | 45 - 50        | 0.75%          |
| 51 - 54        | 1.63%          | 51 - 54        | 0.10%          |
| 55 - 59        | 3.92%          | 55 - 59        | 0.03%          |

Mortality rates are as per Indian Assured lives Mortality (2012-14) Ult [March 31, 2024: Indian Assured lives Mortality (2012-14) Ult]

The estimates of future salary increases, considered in actuarial valuation take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

**Sensitivity analysis**

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation as shown below:


|                      | March 31, 2025 |               | March 31, 2024 |               |
|----------------------|----------------|---------------|----------------|---------------|
|                      | 0.5% Increase  | 0.5% Decrease | 0.5% Increase  | 0.5% Decrease |
| Discount rate        | (4.70%)        | 5.09%         | (5.79%)        | 6.34%         |
| Future salary growth | 5.10%          | (4.75%)       | 6.39%          | (5.88%)       |

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

**Maturity profile of defined benefit obligation:**

|                        | March 31, 2025 | March 31, 2024 |
|------------------------|----------------|----------------|
| Within 1 year          | 1.19           | 0.67           |
| Between 2 and 5 years  | 5.29           | 3.33           |
| Between 6 and 10 years | 5.05           | 3.75           |
| Beyond 10 years        | 24.39          | 29.94          |

The average duration of the defined benefit planned obligations at the end of the reporting period is 9.78 years (March 31, 2024 : 12.11 years)



**35 Fair values and hierarchy**

Accounting classification and fair value of financial instruments is as follows. The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair value:

- The fair value of the quoted mutual funds are at Level 1 of Fair value hierarchy and are measured based on Net Asset Value (NAV) in active markets at the reporting date.

- The fair value of the financial assets (other than mutual funds) and financial liabilities were based on amortised cost at the reporting date.

The following table provides the fair value measurement hierarchy of financial assets and liabilities of the Company:

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2025:

| March 31, 2025                                    |               |          |          | (₹ in crores) |
|---|---------------|----------|----------|---------------|
|   | Level 1       | Level 2  | Level 3  | Total         |
| <b>Financial assets (at FVTPL)</b>                |               |          |          |               |
| Investment in mutual funds (quoted) (non-current) | 18.65         | -        | -        | 18.65         |
| Investment in mutual funds (quoted) (current)     | 399.07        | -        | -        | 399.07        |
|   | <b>417.72</b> | <b>-</b> | <b>-</b> | <b>417.72</b> |

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2024:

| March 31, 2024                                    |              |          |          | (₹ in crores) |
|---|--------------|----------|----------|---------------|
|   | Level 1      | Level 2  | Level 3  | Total         |
| <b>Financial assets (at FVTPL)</b>                |              |          |          |               |
| Investment in mutual funds (quoted) (non-current) | 14.95        | -        | -        | 14.95         |
| Investment in mutual funds (quoted) (current)     | 61.40        | -        | -        | 61.40         |
|   | <b>76.35</b> | <b>-</b> | <b>-</b> | <b>76.35</b>  |

Set out below, is a comparison by class of the carrying amounts and fair value of the Company's financial instruments:

| As at March 31, 2025   | Note | (₹ in crores)  |                 |                 |
|--|------|----------------|-----------------|-----------------|
|  |      | Carrying value |                 |                 |
|  |      | FVTPL          | Amortised Cost  | Total           |
| <b>Financial assets: *</b>                                       |      |                |                 |                 |
| Investment in mutual funds (quoted) (non-current)                | 5.1  | 18.65          | -               | 18.65           |
| Loans (non-current)  | 5.2  | -              | 12.41           | 12.41           |
| Other Financial assets (non-current)                             | 5.3  | -              | 25.60           | 25.60           |
| Investment in mutual funds (quoted) (current)                    | 10.1 | 399.07         | -               | 399.07          |
| Trade receivables  | 10.2 | -              | 109.47          | 109.47          |
| Cash and cash equivalents  | 10.3 | -              | 65.21           | 65.21           |
| Loans (current)  | 10.5 | -              | 0.26            | 0.26            |
| Other financial assets (current)                                 | 10.6 | -              | 12.52           | 12.52           |
|  |      | <b>417.72</b>  | <b>225.47</b>   | <b>643.19</b>   |
| <b>Financial liabilities:</b>                                    |      |                |                 |                 |
| Borrowings (includes current maturities of long-term borrowings) | 14.1 | -              | 469.46          | 469.46          |
| Lease liabilities (Non-current and current)                      | 14.2 | -              | 585.85          | 585.85          |
| Trade payables   | 17.2 | -              | 275.00          | 275.00          |
| Other financial liabilities (current)                            | 18   | -              | 22.56           | 22.56           |
|  |      | <b>-</b>       | <b>1,352.87</b> | <b>1,352.87</b> |

\* excludes investment in equity instruments



As at March 31, 2024

(₹ in crores)

|  | Note | Carrying value |                 |                 |
|--|------|----------------|-----------------|-----------------|
|  |      | FVTPL          | Amortised Cost  | Total           |
| <b>Financial assets: *</b>                                       |      |                |                 |                 |
| Investment in mutual funds (quoted) (non-current)                | 5.1  | 14.95          | -               | 14.95           |
| Loans (non-current)  | 5.2  | -              | 33.46           | 33.46           |
| Other financial assets (non-current)                             | 5.3  | -              | 24.69           | 24.69           |
| Investment in mutual funds (quoted)                              | 10.1 | 61.40          | -               | 61.40           |
| Trade receivables  | 10.2 | -              | 84.31           | 84.31           |
| Cash and cash equivalents  | 10.3 | -              | 60.94           | 60.94           |
| Bank balances other than cash and cash equivalents               | 10.4 | -              | 7.90            | 7.90            |
| Loans (current)  | 10.5 | -              | 0.20            | 0.20            |
| Other Financial assets (current)                                 | 10.6 | -              | 3.89            | 3.89            |
|  |      | <b>76.35</b>   | <b>215.39</b>   | <b>291.74</b>   |
| <b>Financial liabilities:</b>                                    |      |                |                 |                 |
| Borrowings (includes current maturities of long-term borrowings) | 14.1 | -              | 429.10          | 429.10          |
| Lease liabilities (Non-current and current)                      | 14.2 | -              | 569.51          | 569.51          |
| Trade payables   | 17.2 | -              | 357.66          | 357.66          |
| Other financial liabilities (current)                            | 18   | -              | 8.56            | 8.56            |
|  |      | -              | <b>1,364.83</b> | <b>1,364.83</b> |


\* excludes investment in equity instruments

The Company does not have any financial instruments which are measured at FVTOCI

There have been no transfers among Level 1, Level 2 and Level 3 during the year ended March 31, 2025 and year ended March 31, 2024

The management assessed that fair value of cash and cash equivalents and bank balances other than cash and cash equivalents, trade receivables, trade payables and other financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

(This space has been intentionally left blank)



36 Financial risk management

The Company's principal financial liabilities, comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include loans, investments, trade and other receivables and cash and cash equivalents that are derived directly from its operations.

The Company's activities expose it to market risk, credit risk and liquidity risk. The Company's management oversees the management of these risk and works towards minimizing the potential adverse effects, if any, on its financial performance.

A. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises interest rate risk and currency rate risk. Financial instruments affected by market risk include loans and borrowings, payables, investments and deposits. The sensitivity analyses in the following sections relate to the position as at March 31, 2025 and March 31, 2024. The sensitivity of the relevant Profit and Loss item is the effect of the assumed changes in the respective market risks. This is based on the financial assets and financial liabilities held as of March 31, 2025 and March 31, 2024.

(i) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates in form of Term loans.

Exposure to interest rate risk

The interest rate profile of the Company's interest-bearing financial instruments are as follows

|   | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| <b>Fixed rate instruments</b>   |                |                |
| <b>Financial asset</b>  |                |                |
| Margin money deposits with banks  | 11.70          | 2.81           |
| Bank deposits due to mature within twelve months from the reporting date      | 7.90           | 7.90           |
| Deposits with banks due to mature after twelve months from the reporting date | 7.23           | 6.78           |
| Deposits with original maturity of less than three months                     | 30.00          | 10.00          |

|                                      | (₹ in crores)  |                |
|--------------------------------------|----------------|----------------|
|                                      | March 31, 2025 | March 31, 2024 |
| <b>Variable rate instruments</b>     |                |                |
| <b>Financial asset</b>               |                |                |
| ICD given to related parties         | 12.41          | 33.46          |
| Investments in mutual funds (quoted) | 417.72         | 76.35          |
| <b>Financial liability</b>           |                |                |
| Borrowings (non-current and current) | 469.46         | 429.10         |

Sensitivity analysis for fixed rate instruments

Based on the closing balance of variable instruments, an increase/ decrease in interest rate by 1%, with all other variables remaining constant would result in increase/ decrease in interest cost by ₹ 0.49 crores (year ended March 31, 2024: ₹ 0.27 crores)

Sensitivity analysis for variable rate instruments

Based on the closing balance of variable instruments, an increase/ decrease in interest rate by 1%, with all other variables remaining constant would result in increase/ decrease in interest cost by ₹ 0.39 crores (year ended March 31, 2024: ₹ 5.39 crores)

(ii) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in a foreign currency)

Particulars of unhedged foreign currency exposure as at the reporting date:

| Particulars       | March 31, 2025 |               |               |               | March 31, 2024 |               |
|-------------------|----------------|---------------|---------------|---------------|----------------|---------------|
|                   | USD (million)  | (₹ in crores) | EUR (million) | (₹ in crores) | USD million    | (₹ in crores) |
| Capital creditors | 0.03           | 0.30          | 0.70          | 5.70          | 0.06           | 0.48          |
| Capital advances  | -              | -             | -             | -             | 0.01           | 0.04          |

Foreign currency risk sensitivity

The sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments. The following table demonstrates the sensitivity to a reasonably possible change in USD exchange rates, with all other variables held constant

Depreciation of INR against USD by 1% results in decrease in profit before tax by ₹ 0.01 crores (March 31, 2024: Nil) and appreciation of INR against USD by 1% results in increase by such amount.

B. Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its trade receivables, cash and cash equivalents and financial assets.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the management.

(i) Trade and other receivables:


The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of trade and other receivables based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from trade receivables amounting to ₹ 108.61 crores (March 31, 2024 ₹ 84.13 crores). The movement in allowance for impairment in respect of trade and other receivables during the year was as follows:

|  | (₹ in crores)  |                |
|--|----------------|----------------|
|  | March 31, 2025 | March 31, 2024 |
| Opening balance  | 14.52          | 14.87          |
| Loss allowance on trade receivables (net of reversals) | 4.76           | (0.35)         |
| Closing balance  | 19.28          | 14.52          |

There is no significant concentration of credit risk and no single customer accounted for more than 10% of the revenue as of March 31, 2025 and March 31, 2024.

(ii) Financial instruments and deposits:

Credit risk on cash and cash equivalents is limited as the Company generally transacts with banks with high credit ratings assigned by international and domestic credit rating agencies. Investments of surplus funds, temporarily, are made only with approved counterparties who meet the minimum threshold requirements under the counterparty risk assessment process.



C. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Also, the Company has unutilized credit limits with banks.

The table below summarises the maturity profile of the Company's financial liabilities based on undiscounted contractual payments:

|  | (₹ in crores)    |                  |          |
|--|------------------|------------------|----------|
|  | March 31, 2025   |                  |          |
|  | Less than 1 year | More than 1 year | Total    |
| Borrowings (includes current maturities of long-term borrowings) | 98.18            | 590.20           | 688.38   |
| Lease liabilities (non-current and current)                      | 72.57            | 2,009.62         | 2,082.19 |
| Trade payables   | 275.00           | -                | 275.00   |
| Other financial liabilities (current)                            | 22.56            | -                | 22.56    |

|  | (₹ in crores)    |                  |          |
|--|------------------|------------------|----------|
|  | March 31, 2024   |                  |          |
|  | Less than 1 year | More than 1 year | Total    |
| Borrowings (includes current maturities of long-term borrowings) | 89.62            | 505.84           | 595.46   |
| Lease liabilities (non-current and current)                      | 68.86            | 2,062.13         | 2,130.99 |
| Trade payables   | 357.66           | -                | 357.66   |
| Other financial liabilities (current)                            | 8.56             | -                | 8.56     |

37A Capital management

The primary objective of Company's capital management is to ensure that it maintains an optimum financing structure and healthy returns in order to support its business and maximize shareholder value.

The Company manages its capital structure and makes adjustments, in light of the changes in economic conditions or business requirements.

The Company monitors capital using a gearing ratio which is net debt divided by total equity plus net debt as shown below.

- Net debt includes borrowings, lease liabilities (non-current and current) less cash and cash equivalents and
- Total equity comprises of issued share capital and all other equity components attributable to equity share holder.

|   | (₹ in crores)   |                 |
|---|-----------------|-----------------|
|   | March 31, 2025  | March 31, 2024  |
| Borrowings (note 14.1)  | 469.46          | 429.10          |
| Lease liabilities (note 14.2)   | 585.85          | 569.51          |
| Less: Cash and cash equivalents (note 10.3)   | (65.21)         | (60.94)         |
| Less: Investment in mutual funds (quoted) (refer note 5.1 & 10.1)                         | (417.72)        | (76.35)         |
| <b>Net debt (A)</b>   | <b>572.38</b>   | <b>861.32</b>   |
| Total equity attributable to the equity shareholders of the Company (note 12 and note 13) | 1,250.63        | 920.43          |
| <b>Total capital (B)</b>  | <b>1,250.63</b> | <b>920.43</b>   |
| <b>Capital and net debt (C = A+B)</b>   | <b>1,823.01</b> | <b>1,781.75</b> |
| <b>Gearing ratio (D = A / C)</b>  | <b>31%</b>      | <b>48%</b>      |

37B During the year ended March 31, 2023, the Income tax department conducted a search under section 132 of the Income tax Act, 1961 at the registered office of the Company and one hospital location. During the course of the search proceedings, certain information and documents were sought by the department. On March 29, 2024, Company has received the assessment order comprising demand u/s 156 of the Income Tax Act, 1961 for the Assessment Year (AY) 2019-20 amounting to Rs. 1.68 crore (including interest) & for AY 2022-23 amounting to Rs. NIL towards disallowance of certain expenses. On March 3, 2025, the Company has received assessment order with respect of above mentioned matter, comprising demand u/s 156 of the Income Tax Act, 1961 for AY 2020-21 amounting to Rs. 0.39 crore (including interest), for AY 2021-22 amounting to Rs. NIL and for AY 2023-24 amounting to Rs. 0.67 crore (including interest) towards disallowance of certain expenses. The company has filed an appeals with CIT (A).

The Company is confident that its position will be upheld for above income tax litigations and accordingly no provision has been made in the financial statements.

(This space has been intentionally left blank)



38 Segment information:

The Board of Directors of the Company has been identified as the Chief Operating Decision Maker (CODM) as defined by Ind AS 108, Operating Segments. The CODM evaluates the Company's performance and allocates resources based on an analysis of healthcare services in India.

The Company is primarily engaged in a single segment (business and geographical) i.e., Healthcare services in India. As the Company's business activity primarily falls within a single business and geographical segment, there are no additional disclosures to be provided in terms of Ind AS 108 on 'Operating Segments'.

39 Corporate Social Responsibility ('CSR') expenditure

Consequent to the requirements of Section 135 and Schedule VII of the Companies Act, 2013, the Company is required to contribute 2% of its average net profits during the immediately three preceding financial years in pursuance of its Corporate Social Responsibility Policy.

(a) Gross amount required to be spent by the Company during the year is ₹ 4.59 crores (March 31, 2024: ₹ 2.45 crore).

(b) Amount spent:

Promoting healthcare, education, gender equality, ensuring environment sustainability, training for rural sports and rural development objects.

|                           | (₹ in crores) |                        |       |
|---------------------------|---------------|------------------------|-------|
|                           | In cash       | Yet to be paid in cash | Total |
| Year ended March 31, 2025 | 4.59          | -                      | 4.59  |
| Year ended March 31, 2024 | 2.45          | -                      | 2.45  |

(c) Details related to spent / unspent obligations:

|   | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| (i) Contribution to Public Trust                      | -              | -              |
| (ii) Contribution to Charitable Trust (refer note 31) | 4.59           | 2.45           |
| (iii) Unspent amount in relation to:                  |                |                |
| - Ongoing project                                     | -              | -              |
| - Other than ongoing project                          | -              | -              |
|   | 4.59           | 2.45           |

Details of other than ongoing project

As on March 31, 2025

|                 | Amount deposited in Specified Fund of Sch. vii within 6 months | Amount required to be spent during the year | Amount spent during the year | Closing balance |
|-----------------|--|---|------------------------------|-----------------|
| Opening balance | -  | 4.59  | 4.59                         | -               |

As on March 31, 2024

|                 | Amount deposited in Specified Fund of Sch. vii within 6 months | Amount required to be spent during the year | Amount spent during the year | Closing balance |
|-----------------|--|---|------------------------------|-----------------|
| Opening balance | -  | 2.45  | 2.45                         | -               |

40 Reconciliation of movements of liabilities to cash flows arising from financial liabilities

|   | (₹ in crores) |                 |                                    |                 |
|---|---------------|-----------------|------------------------------------|-----------------|
|   | Term loans    | Lease liability | Loan for purchase of capital asset | Total           |
| <b>Debt as at April 01, 2024</b>                  | <b>427.24</b> | <b>569.51</b>   | <b>1.86</b>                        | <b>998.61</b>   |
| Interest accrued but not due as at March 31, 2024 | 0.09          | -               | -                                  | 0.09            |
| Addition during the year                          | 94.24         | 18.70           | 0.45                               | 113.39          |
| <b>Cash flows including interest paid</b>         |               |                 |                                    |                 |
| - Repayment of borrowings                         | (54.46)       | (11.72)         | (0.32)                             | (66.50)         |
| - Interest paid                                   | (35.79)       | (60.29)         | (0.16)                             | (96.24)         |
| <b>Non-cash changes</b>                           |               |                 |                                    |                 |
| - Lease termination/adjustments                   | -             | (0.46)          | -                                  | (0.46)          |
| - Interest expense                                | 36.21         | 70.11           | 0.16                               | 106.48          |
| Interest accrued but not due as at March 31, 2025 | (0.06)        | -               | -                                  | (0.06)          |
| <b>Debt as at March 31, 2025</b>                  | <b>467.47</b> | <b>585.85</b>   | <b>1.99</b>                        | <b>1,055.31</b> |
|   | Term loans    | Lease liability | Loan for purchase of capital asset | Total           |
| <b>Debt as at April 01, 2023</b>                  | <b>375.11</b> | <b>537.45</b>   | <b>0.50</b>                        | <b>913.06</b>   |
| Interest accrued but not due as at March 31, 2023 | 1.33          | -               | -                                  | 1.33            |
| Addition during the year                          | 108.76        | 33.40           | 1.68                               | 143.84          |
| <b>Cash flows including interest paid</b>         |               |                 |                                    |                 |
| - Repayment of borrowings                         | (56.63)       | (8.17)          | (0.32)                             | (65.12)         |
| - Interest paid                                   | (37.66)       | (57.22)         | (0.11)                             | (94.99)         |
| <b>Non-cash changes</b>                           |               |                 |                                    |                 |
| - Lease termination/adjustments                   | -             | (2.23)          | -                                  | (2.23)          |
| - Interest expense                                | 36.42         | 66.28           | 0.11                               | 102.81          |
| Interest accrued but not due as at March 31, 2024 | (0.09)        | -               | -                                  | (0.09)          |
| <b>Debt as at March 31, 2024</b>                  | <b>427.24</b> | <b>569.51</b>   | <b>1.86</b>                        | <b>998.61</b>   |

41 Below are the details of subsidiary along with proportion of ownership interest held and country of incorporation

Investment in subsidiary:

| Name of the Company | Country of Incorporation | Percentage of ownership interest held (directly and indirectly) and voting rights held as at |                |
|---------------------|--------------------------|--|----------------|
|                     |                          | March 31, 2025   | March 31, 2024 |
| MHEIPL              | India                    | 84.07%   | 84.07%         |



42 Accounting ratios

**i) Current ratio**

The current ratio is used to assess a company's short term liquidity. It is calculated by dividing the current assets by current liabilities.

**ii) Debt-equity ratio**

"Total debt" is defined as aggregate of non-current borrowings and current maturities of long term-borrowings and total equity includes issued capital and all other equity reserves.

**iii) Debt service coverage ratio**

The Debt Service Coverage Ratio (DSCR) measures the ability of a company to use its operating income to repay all its debt obligations, including repayment of principal and interest on both short-term and long-term debt. It is calculated by dividing net operating income by the total debt service (Interest and principal).

**iv) Return on equity ratio**

Equal to profit for the year divided by the equity during that period, and is expressed as a percentage.

**v) Inventory turnover ratio**

Inventory turnover indicates the rate at which a company sells and replaces its stock of goods during a particular period. The inventory turnover ratio formula is the cost of goods sold divided by the average inventory for the same period.

**vi) Trade receivables turnover ratio**

Accounts receivable turnover ratio is calculated by dividing your revenue from operations by your average accounts receivable. The ratio is used to measure how effective a company is at extending credits and collecting debts.

**vii) Trade payables turnover ratio**

This ratio is used to measure the number of times the business is paying off its creditors or suppliers in an accounting period. It is computed by dividing the total purchases by average accounts payable.

**viii) Net capital turnover ratio**

It is calculated by dividing annual sales by average stockholder equity (net worth). The ratio indicates how much a company could grow its current capital investment level.

**ix) Net profit ratio**

The net profit percentage is the ratio of after-tax profits to net sales. It reveals the remaining profit after all costs of production, administration, and financing have been deducted from sales, and income taxes recognized.


**x) Return on capital employed**

Return on Capital Employed is calculated by dividing our EBIT during a given period by Capital Employed (net worth, total debt, deferred tax liability) during that period.

**xi) Return on investment**

Return on investment (ROI) is a performance measure used to evaluate the efficiency or profitability of an investment or compare the efficiency of a number of different investments. To calculate ROI, the benefit (or return) of an investment is divided by the cost of the investment.

| Ratio                                | Numerator   | Denominator  | As at<br>March 31, 2025 | As at<br>March 31, 2024 | % change | Reason for variance  |
|--------------------------------------|---|--|-------------------------|-------------------------|----------|--|
| i) Current ratio                     | Current assets  | Current liabilities  | 1.55                    | 0.60                    | 159%     | The variance is due to increase in Investments in mutual funds                                 |
| ii) Debt-equity ratio                | Total Debt  | Total Equity   | 0.38                    | 0.47                    | 19%      | NA   |
| iii) Debt service coverage ratio     | Earnings available for debt service=<br>Net Profit after tax+ Non cash<br>operating expenses+ Interest +<br>Other adjustments like loss on sale<br>of fixed assets, etc | Debt service= Interest &<br>lease payments + Principal<br>Repayments     | 3.24                    | 2.43                    | 33%      | The variance is due to increase in profit for the year   |
| iv) Return on equity ratio %         | Net Profit after tax  | Average Shareholders<br>equity   | 0.31                    | 0.29                    | -5%      | NA   |
| v) Inventory turnover ratio          | Cost of Goods sold = opening<br>inventory + purchases - closing<br>inventory  | Average Inventory  | 12.39                   | 11.50                   | 8%       | NA   |
| vi) Trade receivables turnover ratio | Revenue from operations   | Average Accounts<br>Receivable   | 22.23                   | 22.25                   | 0%       | NA   |
| vii) Trade payables turnover ratio   | Total Purchases   | Average Trade Payables   | 1.15                    | 1.05                    | 9%       | NA   |
| viii) Net capital turnover ratio     | Net sales   | Average Shareholders<br>equity   | 1.98                    | 2.22                    | -11%     | NA   |
| ix) Net profit ratio %               | Net Profit  | Net Sales  | 15.38%                  | 13.09%                  | -18%     | NA   |
| x) Return on capital employed %      | Earnings before interest and taxes  | Capital Employed = Net<br>Worth + Total Debt +<br>Deferred Tax Liability | 32.26%                  | 32.95%                  | -2%      | NA   |
| xi) Return on investment %           | Interest (Finance Income)   | Investment in fixed<br>deposits  | 2.98%                   | 5.02%                   | -41%     | The variance is due to increase in investment in Bank deposits during the month of March 2025. |



43 Dues to Micro and Small Enterprises as per the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED):

|   | (₹ in crores)  |                |
|---|----------------|----------------|
|   | March 31, 2025 | March 31, 2024 |
| (i) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end  | 6.11           | 5.40           |
| (ii) Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end   | -              | -              |
| (iii) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year                                  | -              | -              |
| (iv) Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year | -              | -              |
| (v) Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year             | -              | -              |
| (vi) Interest due and payable towards suppliers registered under MSMED Act, for payments already made   | -              | -              |
| (vii) Further interest remaining due and payable for earlier years  | -              | -              |

44 Other Statutory Information

- (i) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company do not have any transactions with companies struck off under section 248 of Companies Act, 2013 or section 560 of Companies Act, 1956.
- (iii) The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period,
- (iv) The Company is in compliance with number of layers of companies, as prescribed under clause (87) of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017,
- (v) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (vi) During the year ended March 31, 2025, no funds have been advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- The Company has complied with relevant provisions of the applicable law for this transaction. The Company has complied with relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999), to the extent applicable, the Companies Act, 2013 for such transaction and this transaction is not violative of the Prevention of Money-Laundering Act, 2002 (15 of 2003)
- (vii) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- (viii) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961
- (ix) The Company has not been declared wilful defaulter by any bank or financial institution or other lender.

45 During the year ended March 31, 2024, the Company has acquired 84.07% shareholding in MHEIPL and consequently MHEIPL has become the subsidiary of the Company. The Company has not prepared the Consolidated Financial Statements for the year ended March 31, 2025 as required under Ind AS 110 - Consolidated Financial Statements. The Company has availed the exemption available under Ind AS 110 whereby MHEIPL shall be included in the consolidated financial statement of MHEIPL, Holding Company. For this purpose, the shareholders of the Company has provided consent for consolidation of MHEIPL in MHEIPL.


As per our report of even date attached

For B S R & Co. LLP  
Chartered Accountants  
Firm Registration number : 101248W/W - 100022



Siddhartha Sharma  
Partner  
Membership number: 118756

For and on behalf of the Board of Directors of  
Manipal Hospitals Private Limited



Sameer Agarwal  
Director  
DIN: 07554053

Dr. H. Sudarshan Ballal  
Director  
DIN: 01195055



Khadija G Vahora  
Company Secretary  
Membership number: A37266

Place : Bengaluru  
Date : May 27, 2025

Place : Bengaluru  
Date : May 27, 2025